Document:

Amyris 2013 10-K Ex 10.24 LicenseAgreementAmyristoJVCO12-02-13FINAL

EXECUTION COPY
	
			
	CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

LICENSE AGREEMENT
This License Agreement (the “Agreement”) is entered into on December 2, 2013 (the “Effective Date”) by and among AMYRIS, INC., a corporation organized and existing under the laws of the state of Delaware, United States of America, with its principal place of business at 5885 Hollis Street, Suite 100, Emeryville, California 94608 (“AMYRIS”),  and Total Amyris BioSolutions B.V., a private company with limited liability under the laws of the Netherlands (besloten vennootschap met beperkte aansprakelijkheid), co-owned, as of the Effective Date, by Amyris and Total Energies Nouvelles Activités USA,  with its principal place of business at Claude Debussylaan 24, 1082 MD Amsterdam, the Netherlands (the “Company”).  AMYRIS and Company may each be referred to herein individually as a “Party,” and collectively as the “Parties.” 
BACKGROUND
WHEREAS, AMYRIS and Total Gas & Power USA Biotech, Inc. entered into a technology license, research, development, commercialization and collaboration relationship pursuant to that certain Technology License, Development, Research and Collaboration Agreement, dated as of June 21, 2010 (as such agreement may be amended from time to time by the parties thereto, including as amended pursuant to the Second Amendment (as defined below), the “Collaboration Agreement”), which Collaboration Agreement was assigned by Total Gas & Power USA Biotech, Inc. to Total Gas & Power USA SAS, which is now called Total Energies Nouvelles Activités USA (“TOTAL”), by letter agreement dated January 11, 2011;
WHEREAS, the Collaboration Agreement contemplates that AMYRIS and TOTAL may form one or more joint venture companies to exploit certain technologies resulting from research and development activities conducted under the Collaboration Agreement;
WHEREAS as of July 30, 2012, AMYRIS and Total Gas & Power USA, SAS entered into a Master Framework Agreement (as amended as prior to or as of the Effective Date, “Master Framework Agreement”) and that certain Second Amendment to the Collaboration Agreement dated as of July 31, 2012 (“Second Amendment”), which agreements contemplated that AMYRIS would grant to a joint venture entity certain licenses and other rights to use certain intellectual property of AMYRIS to Make and Sell the JV Products and conduct certain related activities, in each case, according to the terms and conditions set forth in a license agreement; 
WHEREAS, in order to make such license grants and to address certain related matters, the Parties desire to enter into this Agreement, subject to the terms and conditions hereof; and 
WHEREAS, of even date herewith, AMYRIS, TOTAL and Company are entering into an initial shareholders’ agreement (the “Company Shareholders’ Agreement”), establishing a Dutch BV jointly owned by AMYRIS and TOTAL. 

1

WHEREAS, of even date herewith, AMYRIS and Total Energies Nouvelles Activités USA (formerly known as Total Gas & Power USA, SAS), a société par actions simplifiée organized under the laws of the Republic of France (“TENA”) have entered into a letter agreement to clarify (i) the obligations of AMYRIS with regard to the restrictions to be incorporated in its future agreements regarding the production and commercialization of farnesene and/or farnesane and (ii) Section 4.1 of the IP License Agreement (as defined below) including the purchase obligations contained therein.
NOW, THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
Article 1.DEFINITIONS
1.1    Capitalized terms used but not defined herein shall have the meanings set forth in the Company Shareholders’ Agreement.  References to definitions in the Master Framework Agreement, Company Shareholders’ Agreement and/or the Collaboration Agreement, including the Second Amendment, are to such definitions as they exist as of the Effective Date.  
1.2    “Affiliate” shall have the meaning set forth in Section 1.1 of the Collaboration Agreement; except that (i) Novvi LLC and its Affiliates (collectively, “Novvi”) shall not be deemed an Affiliate of AMYRIS under this Agreement unless AMYRIS’ equity ownership of a Novvi entity exceeds 50%, at which time, the applicable Novvi entity(ies) will be considered an Affiliate of AMYRIS for purposes of this Agreement and (ii) Company shall not be considered an Affiliate of AMYRIS nor an Affiliate of TOTAL and neither TOTAL nor AMYRIS shall be considered an Affiliate of Company.  For clarity, the Affiliates of AMYRIS as of the Effective Date include:  AMYRIS Fuels LLC, AB Technologies LLC, AMYRIS Brasil Ltda., SMA Indústria Química S.A  
1.3    “Amended and Restated Novvi Side Letter” means the letter, dated November 30, 2013, from AMYRIS to Novvi LLC and Company.
1.4    “AMYRIS Certification Materials” means the Diesel Certification Materials and Jet Certification Materials (each as defined in Section 7 of the Second Amendment).
1.5    “AMYRIS Competitor” means an entity (other than AMYRIS or its Affiliates) whose primary business is to use a synthetic biology platform to make genetically modified microorganisms and to use such genetically modified microorganisms to make Compounds that compete with AMYRIS Compounds.
1.6    “AMYRIS Family” means AMYRIS and its Affiliates.  
1.7    “AMYRIS Farnesene Included IP” means any (i) AMYRIS Background IP and any AMYRIS Non-Collaboration IP, in each case that is Controlled by AMYRIS or its Affiliates as of the Second Amendment Date, and (ii) AMYRIS Non-Collaboration IP 

2

developed after the Second Amendment  Date (other than by a Third Party Acquirer), in each case, that (x) encompass general means of practicing synthetic biology or (y) are necessary or useful for the R&D Activities contemplated in connection with the Biofene Development Project.
1.8    “AMYRIS Farnesene Production IP” means any Farnesene Production IP owned or Controlled by AMYRIS or its Affiliates (other than a Third Party Acquirer).
1.9    “AMYRIS Hydrogenation IP” means any AMYRIS Background IP and AMYRIS Non-Collaboration IP in each case that is Controlled by AMYRIS or its Affiliates (other than a Third Party Acquirer) and is necessary or materially useful in order to hydrogenate farnesene into farnesane.  
1.10    “AMYRIS Included IP” shall have the meaning provided in Section 1.4 of the Collaboration Agreement.  
1.11    “AMYRIS Licensed IP” means, all Inventions to the extent owned or Controlled by AMYRIS or its Affiliates (other than a Third Party Acquirer) as of the Effective Date or at any time thereafter during the Term until thirty (30) years following the Effective Date including, AMYRIS Technology (as defined in Section 1.11 of the Collaboration Agreement), AMYRIS-Owned Collaboration IP (as defined in Section 1.9 of the Collaboration Agreement), AMYRIS Hydrogenation IP, AMYRIS-Owned Improvement Scope IP, AMYRIS’ interest in Jointly-Owned Improvement Scope IP (as defined in Section 6.1(e) of the Collaboration Agreement), Jointly Owned Collaboration IP (as defined in Section 6.1(d)(ii) of the Collaboration Agreement), AMYRIS Farnesene Included IP and AMYRIS Production IP (as defined herein), and any Invention(s) licensed to AMYRIS by Novvi pursuant to the IP License Agreement entered by AMYRIS and Novvi on March 26, 2013, as amended by the Amended and Restated Novvi Side Letter (the “IP License Agreement”), and subject to the terms of Section 2.A(vi) below, the AMYRIS Certification Materials (but in the case of the AMYRIS Certification Materials, solely for use as contemplated in Section 9.B of the Second Amendment), in each case that is necessary or, in the case of the AMYRIS Farnesene Production IP, useful (i) to develop and/or optimize the processes of making farnesene from the Commercial Farnesene Strain and purifying it from the fermentation broth and converting farnesene into farnesane and/or (ii) to Make and Sell (as defined in Section 1.75 of the Collaboration Agreement) JV Products; provided that if there is a Jet Go Decision, then any such Inventions first developed or Controlled by AMYRIS or its Affiliates after the date of the Jet Go Decision shall be included in the AMYRIS Licensed IP only if Company agrees to pay to AMYRIS a commercially reasonable royalty (to be determined with regard to any such Invention(s) following the development of the applicable Invention(s) pursuant to Section 2.A(iii)).  For purposes of this definition and for Sections 2(A)(i)(a), 2(A)(i)(c) and 7(D), an item of AMYRIS Licensed IP will be deemed to be necessary with respect to a particular activity if it is actually used by the Company in carrying out such activity.
1.12    “AMYRIS-Owned Improvement Scope IP” means any and all Improvement Scope IP that is owned by AMYRIS pursuant to Section 6.1(e) of the Collaboration Agreement.

3

1.13    “Banked Strain” has the meaning set forth in Section 2.D hereof.
1.14    “Biofene Development Project” means the project and activities described in the Biofene Development Project Plan.
1.15    “Biofene Development Project Plan” means the written Development Project Plan agreed by AMYRIS and TOTAL for the research, development, and scale-up production activities to be conducted pursuant to the Second Amendment (as amended from time to time, if applicable, pursuant to the Collaboration Agreement).
1.16    “Brazil Business” means production and commercialization of Farnesane Diesel Products and Farnesane Jet Products within Brazil for commercialization solely in Brazil.  The Brazil Business shall include the right to produce Farnesane Diesel Products and Farnesane Jet Products outside of Brazil for commercialization within Brazil, but shall exclude the right to produce Farnesane Diesel Products and Farnesane Jet Products within Brazil for commercialization outside of Brazil (it being understood that the commercialization of Farnesane Diesel Products and Farnesane Jet Products for use in vehicles which begin an international travel segment within Brazil and conclude such international travel segment outside of Brazil shall constitute commercialization of such products within Brazil). 
1.17    “Buy-Out Closing” means the closing of TOTAL’s purchase of all of AMYRIS’ interest in the Company pursuant to (a) Section 7.02 of the Company Shareholders’ Agreement in the case of a deadlock; (b) Articles 9.3 (Purchase Option), or 9.6 (Right of First Offer) of the Company’s Articles of Association; (c) a foreclosure under the Pledge Agreement; or (d) Section 8.03 of the Company Shareholders’ Agreement.  
1.18    “By-Product” means any composition other than a JV Product that is produced (and has been produced in greater than de minimis levels in a manufacturing process that is at least a 300 liter scale) (a) as a direct consequence of the manufacture of a JV Product by the Company or its Affiliates, Subcontractors or sublicensees, and (b) except in the case of dead yeast cells, with a weight that is less than 40% of the weight of the applicable JV Product concurrently produced and, in each case, any composition resulting from further purification processing.
1.19    “Change of Control” means the occurrence of any of the following with respect to AMYRIS: (i) the consolidation of AMYRIS with, or the merger of AMYRIS with or into, another “person” (as such term is used in Rule 13d-3 and Rule 13d-5 of the Exchange Act), or the sale, lease, transfer, conveyance or other disposition, in one or a series of related transactions, of all or substantially all of the assets of the AMYRIS and its subsidiaries taken as a whole, or the consolidation of another “person” with, or the merger of another “person” into, AMYRIS, other than in each case pursuant to a transaction in which the “persons” that “beneficially owned” (as such term is defined in Rule 13d-3 and Rule 13d-5 under the Exchange Act), directly or indirectly, the Voting Shares  of AMYRIS immediately prior to the transaction “beneficially own”, directly or indirectly, Voting Shares representing at least a majority of the total voting power of all outstanding classes of voting stock of the surviving or transferee person; (ii) the adoption by the Company of a 

4

plan relating to the liquidation or dissolution of the Company,  (iii) the consummation of any transaction (including any merger or consolidation) the result of which is that any “person” becomes the “beneficial owner” directly or indirectly, of more than 50% of the Voting Shares of the AMYRIS (measured by voting power rather than number of shares); or (iv) the first day on which a majority of the members of the Board of Directors AMYRIS does not consist of Continuing Directors.  As used in this definition, “Voting Shares” of any Person means capital shares or capital stock of such Person which ordinarily has voting power for the election of directors (or persons performing similar functions) of such Person, whether at all times or only so long as no senior class of securities has such voting power by reason of any contingency.  As used in this definition, “Continuing Director” means, as of any date of determination, any member of the Amyris Board of Directors who (i) was a member of the Amyris Board of Directors on July 31, 2012 or (ii) was nominated for election or elected to the Amyris Board of Directors with the approval of a majority of the Continuing Directors who were members of the Amyris Board of Directors at the time of such nomination or election and who voted with respect to such nomination or election; provided that a majority of the members of the Amyris Board of Directors voting with respect thereto shall at the time have been Continuing Directors.  
1.20    “Commercial Farnesene Strain” means (a) any Commercial Strain (as defined in Section 1.25 of the Collaboration Agreement) designed for the production of farnesene and (b) any Suitable Commercial Strain.
1.21    “Commercial Scale” means with respect to a particular Commercial Farnesene Strain, the use of such Strain to reproducibly produce farnesene of commercially quality in commercial quantities and at commercially reasonable cost, as shown by production of [*].      
1.22    “Commercial Technology Transfer Package” has the meaning set forth in Section 2.D(i).
1.23    “Company’s Articles of Association” means the articles of association of the Company, as amended from time to time. 
1.24    “Company Indemnitees” has the meaning set forth in Section 5.A(ii) hereof.
1.25    “Company Strains” means the Commercial Farnesene Strain(s), the Intermediate Strain(s) and any other Strains that are genetic manipulations or modifications of any of the foregoing.
1.26    “Confidential Information” has the meaning set forth in Section 6.A hereof.  

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

5

1.27    “Control” or “Controlled” means, with respect to any Invention, Patent or other intellectual property right, that the applicable Party or its Affiliates owns or has a license to such Invention, Patent or other intellectual property right and such applicable Party or its Affiliates has the ability to disclose the same to the other Party and to grant the other Party a license or a sublicense (as applicable) under the same as provided in this Agreement without violating the terms of any agreement or other arrangement with any Third Party.
1.28    “Diesel Product” means one or more fermentation-produced isoprenoid(s) that may or may not be hydrogenated or hydroprocessed, which when blended with petroleum diesel, meet the ASTM D975 specification, the EN590 European standard or the equivalent of (or successor to) either such standard, in each case, for use as a diesel fuel.
1.29    “Dispute” means any dispute, claim or controversy that arises between the Parties in connection with this Agreement or any agreement or instrument delivered in connection herewith, or the negotiation, execution, interpretation, breach, termination invalidity or enforcement hereof or thereof.
1.30     “Executive Officers” means (a) in the case of AMYRIS, the Chief Commercial Officer or such other officer designated in writing by the Chief Executive Officer, and (b) in the case of Company, the Chief Executive Officer or such other officer as may be designated by Company’s board of directors. 
1.31    “Farnesane Diesel Product” means a Diesel Product that is farnesane, wherein the isoprenoid is farnesene. 
1.32    “Farnesane Jet Product” means a Jet Product that is farnesane, wherein the isoprenoid is farnesene. 
1.33    “Farnesene Production IP” means any and all (a) AMYRIS Farnesene Included IP, (b) Collaboration IP and (c) Improvement Scope IP, in each case that is necessary or useful to (i) produce farnesene from fermentation of a Farnesene Strain or (ii) purify such farnesene from the fermentation medium to hydrogenation grade.
1.34    “Farnesene Strain” means any Strain that produces farnesene.
1.35    “Field” means diesel fuel and/or jet fuel applications; provided in the case of a Jet Go Decision, the Field shall thereafter not include diesel fuel applications.
1.36    “Governmental Entity” shall have the meaning set forth in Section 1.54 of the Collaboration Agreement. 
1.37    “Improvement Scope IP” means any and all Inventions that are conceived or reduced to practice on or after the Effective Date of the Collaboration Agreement by (a) any employee, agent or Third Party contractor of TOTAL or any of its Affiliates, (b) any employee, agent or Third Party contractor of AMYRIS or any of its Affiliates, or (c) any of the foregoing jointly, in each case, in the performance of Improvement Scope 

6

Activities (x) during the term of the Collaboration Agreement or (y) during the term that a JV Product is being commercialized by Company. 
1.38    “Indemnified Party” has the meaning set forth in Section 5.A(iii) hereof.
1.39    “Indemnifying Party” has the meaning set forth in Section 5.A(iii) hereof.
1.40    “Infringement” has the meaning set forth in Section 3.D(i) hereof.
1.41    “Initial Package” has the meaning in Section 2.D(iii)(a) hereof.  
1.42    “Intermediate Strain(s)” means, at a given point in time, (i) the Farnesene Strain then most recently used by AMYRIS for the commercial Manufacture of farnesene, and (ii) up to three (3) other Strains developed in the Biofene Development Project that are most likely to achieve the goals of the Biofene Development Project.  The Intermediate Strains to be initially escrowed as part of the Initial Package shall be selected by the TOTAL representative(s) to the Management Committee.  Thereafter the Management Committee pursuant to the Second Amendment may periodically designate additional Intermediate Strain(s) for inclusion as Banked Strains to replace any or all of the existing four (4) Banked Strains, provided that if the Management Committee is unable to agree upon whether a particular Strain should be designated as an Intermediate Strain, then the TOTAL representative(s) to the Management Committee shall have the right to make such decision with respect to one (but not more) of the subject Strains but in no event may the TOTAL representatives(s) designate more than one Strain per calendar year as an Intermediate Strain under this proviso.  Notwithstanding the above, at any given time, there shall be no more than four (4) Banked Strains. 
1.43    “Intermediate Strain Technology” means any Invention Controlled by AMYRIS or its Affiliates (other than a Third Party Acquirer) that is necessary or materially useful to perform strain engineering or other genetic manipulation in order to genetically manipulate the Intermediate Strain(s) for the purpose of developing a Suitable Commercial Strain.
1.44    “Invention(s)” means, whether or not patentable, any inventions, information, technology, methods, compositions of matter, formulae and other subject matter (including all related software, workflow, apparatus or arrangement of apparatuses, knowledge database systems, processes, systems and technology for the design, selection, engineering, development and manufacture of Strains, Compounds or Products (each, as defined in the Collaboration Agreement), the Strains and the Compounds and the Products themselves, chemistry, process engineering, materials transformation, Strain or Compound or Product specifications, know-how, trade secrets, improvements and all intellectual property rights therein or pertaining thereto.   
1.45    “IP License Agreement” has the meaning set forth in Section 1.10.
1.46    “Jet Go Decision” means that written notification by TOTAL to AMYRIS that TOTAL has made a No Go Decision with respect to the Farnesene Diesel Product but 

7

wishes to pursue the Farnesene Jet Product, as provided in Section 2.2(b) of the Master Agreement.
1.47    “Jet Product” means one or more fermentation produced isoprenoid(s) that may or may not be hydrogenated or hydroprocessed, which when blended with petroleum-derived jet fuel, meet the ASTM D 1655 specification or the equivalent of (or successor to) such standard for use as a jet fuel.
1.48    “JV Product” means (i) farnesene or farnesane for use in Diesel Product or Jet Product, (ii) Farnesane Diesel Product, or (iii) Farnesane Jet Product.
1.49    “Knowledge” means actual or constructive knowledge of any officer of AMYRIS.
1.50    “Known By-Product” means a By-Product that is specified on Exhibit F as of the Effective Date or added to Exhibit F in accordance with Section 2.H.  
1.51    “Legal Requirement” means, with respect to any Party, any federal, state or local law, constitution, treaty, ordinance, code, edict, writ, decree, rule, regulation, judgment, ruling, injunction or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Entity that is binding upon or applicable to such Party, including Environmental Laws and any of the foregoing applicable to genetically modified microorganisms, related to food, drugs, health or safety. 
1.52    “Lien” means any security interest, pledge, mortgage, lien, charge, adverse claim of ownership or use, or other encumbrance of any kind. 
1.53    “Manufacture” means make and have made (including practicing and using for the foregoing purposes).
1.54    “No-Go Decision” means a written notification by TOTAL to AMYRIS that TOTAL no longer wishes to participate in the Biofene Development Project pursuant to Section 2.2 or 3.3(a) of the Master Framework Agreement or a deemed No-Go Decision pursuant to Section 2.2(d) of the Master Framework Agreement.  

1.55    “Patent(s)” means (a) all national, regional and international patents and patent applications, including provisional patent applications; (b) all patent applications filed either from a patent or patent application described in clause (a) or from an application claiming priority to a patent or patent application described in clause (a), including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications; (c) any and all patents that have issued or in the future issue from the foregoing patent applications (clauses (a) and (b)), including utility models, petty patents and design patents and certificates of invention; (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary 

8

protection certificates and the like) of the foregoing patents or patent applications (clauses (a), (b) and (c)); and (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent applications and patents.  
1.56    “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.
1.57    “Potential Third Party Conflict” has the meaning set forth in Section 2.H(ii).
1.58    “Program Strain” means a Commercial Strain (as defined in Section 1.25 of the Collaboration Agreement) designed for the production of farnesene that satisfies the criteria of a Commercial Farnesene Strain.
1.59    “Related Agreements” means the Company Shareholders’ Agreement and any Related Agreements (as defined in the Company Shareholders’ Agreement) other than this Agreement.    
1.60    “Second Amendment Date” means July 30, 2012. 
1.61    “Strain” means any microorganism, including bacteria, yeast, higher fungi and algae, that is tested, modified or optimized to produce compounds according to the alteration of metabolic pathways, including AMYRIS’ genetically modified yeast strain that includes the Mevalonate Pathway from which it is capable of making an isoprenoid compound.
1.62    “Subcontractor” means any Third Party Subcontractor or TOTAL Subcontractor.
1.63    “Subject Third Party Agreements” shall have the meaning set forth in Section 4.D(i) hereof.
1.64     “Successful Commercial Transfer” means with respect to a particular Commercial Farnesene Strain, the use of such Strain to reproducibly produce farnesene at  Commercial Scale.
1.65    “Successful Interim Transfer” means with respect to a particular Intermediate Strain, the use of such Strain to reproducibly produce farnesene as shown by production of [*].   

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
 

9

1.66    “Suitable Commercial Strain” shall have the meaning set forth in Section 2.A(b) hereof. 
1.67    “Term” has the meaning set forth in Section 7.A hereof.
1.68    “Territory” means worldwide. 
1.69    “Third Party” means a Person other than Company or any of its Affiliates, AMYRIS or TOTAL or an Affiliate of AMYRIS or TOTAL. 
1.70    “Third Party Acquirer” means (i) a Third Party that acquires AMYRIS in a Change of Control or acquires substantially all of the assets of AMYRIS and (ii) any Affiliates of such Third Party (other than the members of AMYRIS Family as of immediately prior to the AMYRIS transaction described in subparagraph (i)).  
1.71    “Third Party Agreements” means any agreement that was entered or is entered by AMYRIS with a Third Party pursuant to which AMYRIS obtained or obtains a license, with the right to sublicense, of any Inventions, including without limitation Patents, within the AMYRIS Licensed IP.
1.72    “Third Party Conflict” has the meaning set forth in Section 2.H(i).
1.73    “Third Party Subcontractor” has the meaning set forth in Section 2.C(ii) hereof.
1.74    “TOTAL Subcontractor” has the meaning set forth in Section 2.C(ii) hereof.
ARTICLE 2.    LICENSE GRANT AND RELATED TERMS
A.    License to Make and Sell JV Products. 
(i)    License Grants.  Subject to Section 2.F and 2.I below and Article 7, AMYRIS and its Affiliates hereby grant to Company the following perpetual and irrevocable worldwide licenses, with the right to sublicense through multiple tiers pursuant to Section 2.C below, for the JV Products:
(a)    a non-exclusive, royalty-free (subject to Section 2.A(iii) and (vi) and Section 2.B below) right and license under the AMYRIS Licensed IP in each case that is necessary or, in the case of the AMYRIS Farnesene Production IP, useful to develop and/or optimize the processes of making farnesene from a Commercial Farnesene Strain, purify farnesene from the fermentation broth, and convert farnesene into farnesane in the Territory; and
(b)    a non-exclusive, royalty-free (subject to Section 2.A(iii) and (vi) and Section 2.B below) right and license under the Intermediate Strain Technology to optimize and/or engineer by any means the Intermediate Strain(s) into a Farnesene Strain that produces farnesene at Commercial Scale (“Suitable Commercial Strain”), which 

10

license may only be practiced if a Buy-Out Closing occurs prior to the completion of the Biofene Development Project and no Program Strain exists at the time of the Buy-Out Closing.  Such license may be practiced only until the date that Commercial Scale is demonstrated for a Suitable Commercial Strain, at which time the license under this clause (b) shall automatically terminate; 
(c)    an exclusive (subject to Section 2.A(iv)), royalty-free (subject to Section 2.A(iii) and (vi) and Section 2.B below) right and license under the AMYRIS Licensed IP in each case that is necessary or, in the case of the AMYRIS Farnesene Production IP, useful to Make and Sell JV Products within the Territory; and
(d)    a non-exclusive, royalty-free (subject to Section 2.B below) right and license under the AMYRIS Licensed IP, in each case, that is necessary to offer for sale, sell and import any Known By-Product(s) for any uses other than for use(s) precluded by Third Party Conflicts; provided, however, that this license shall not expand any obligation that AMYRIS may have to disclose the AMYRIS Licensed IP beyond what is set forth elsewhere in this Agreement.  For clarity, the production of By-Products by Company or its Sublicensees or Subcontractors in connection with the practice of the right to Make JV Products pursuant to Section 2.A(c) above shall not be a breach of this Agreement.     
For clarity, there shall be no volume or production limits on the foregoing licenses set forth in clauses (a), (c) and (d), and such licenses may be practiced by Company and its sublicensees anywhere in the Territory (subject to Section 2.E(iv)) for the licensed uses.
(ii)    Limited License.  The licenses granted Company above (a) allow it to conduct licensed activities with respect to (x) the JV Products solely for use in the Field, and/or (y) Known By-Products (on a case-by-case basis) solely for use outside the applicable Third Party Conflict(s), and (b) include the right to optimize the Company Strains by means of random mutagenesis but not any strain engineering or other method of genetic manipulation (other than in the case of the Intermediate Strains to the extent licensed herein).  Upon termination of the license granted in Section 2.A(i)(b), unless otherwise agreed in writing by the Parties, at AMYRIS’ written request, Company shall destroy all quantities of the Intermediate Strain(s) and any Strains developed under such license based on or using the Intermediate Strain(s) other than the Suitable Commercial Strain(s).
(iii)    Inventions First Developed or Controlled by AMYRIS after Jet Go Decision.  Any Invention(s) first developed or Controlled by AMYRIS or its Affiliates after the date of the Jet Go Decision that would be covered by the AMYRIS Licensed IP or the Intermediate Strain Technology, as applicable, shall be included therein only if the Company (or any successor of Company) agrees to pay a commercially reasonable royalty (to be determined with regard to such Inventions following its development with regard thereto).  AMYRIS shall notify Company (or any successor of Company) of any such Invention(s) promptly as they first are developed or otherwise become Controlled by AMYRIS or its Affiliates, providing a detailed description thereof.  At the request of Company (and/or any successor of Company), the Parties shall negotiate in good faith a 

11

commercially reasonable royalty for the use of such Invention(s).  If the Parties (or AMYRIS (and/or any successor of Company) agree in writing on such terms for inclusion of such Invention(s) within the AMYRIS Licensed IP or the Intermediate Strain Technology, as applicable, then they shall be subject to the applicable licenses in Section 2.A.  If the Parties (or AMYRIS and any successor of Company) are unable to reach agreement on such terms, then at the request of Company (or any successor of Company) such matter shall be submitted to baseball arbitration for final resolution as provided in Section 8.E below.
(iv)    AMYRIS Retained Rights.  AMYRIS retains (A) the co-exclusive right to Make and Sell JV Products in Brazil, unless and until the Brazil Business is contributed to or acquired by the Company or TOTAL in accordance with the terms attached as Exhibit A hereto, (B) the right to conduct activities within the Improvement Scope as permitted under the Collaboration Agreement and the conduct of the Biofene Development Project and (C) for clarity, the exclusive right to Make and Sell and otherwise exploit products for use outside the Field, including the right to Manufacture farnesene and/or farnesane for use in such other products.  The Parties acknowledge that the exclusivity of the license granted in Section 2.A(i)(c) is subject to the limited license granted by AMYRIS to Novvi, per Section 2.1(a)(ii) of the IP License Agreement, to offer for sale, sell, and import any by-products directly resulting from Novvi’s licensed manufacture of base oils, additives and lubricants from farnesene for use in or as diesel or jet fuel to AMYRIS or the Company, subject to the Amended and Restated Novvi Side Letter. 
(v)    General.  
(a)    Survival.  Except as provided in Section 2.A(i)(b) or in Article 7, the licenses granted to Company in Article 2 shall be irrevocable until the end of the Term and remain in full force and effect during the Term, notwithstanding any breach or alleged breach of the Collaboration Agreement or any termination or expiration of the Collaboration Agreement.  For clarity, the licenses granted to Company shall terminate upon the earlier of (i) expiration of the Term and (ii) termination of this Agreement pursuant to Section 7.B or 7.C.  However, during the Term, except for such modifications as may apply under Section 2.I, such licenses shall remain in effect regardless of the equity ownership of Company or any changes thereto. 
(b)    Licensed Patent List.  The Patents existing as of the Effective Date within the AMYRIS Licensed IP are those set forth in a letter provided by AMYRIS to the Company of even date herewith.  Upon the Company first becoming eligible to practice the license granted in Section 2.A(i)(b), AMYRIS shall provide to Company a list of Patents then currently existing within the Intermediate Strain Technology.  During the Term, AMYRIS shall provide to Company at least semi-annually a complete and accurate written updated list of all Patents within the AMYRIS Licensed IP and, if Company is eligible to practice the license granted in Section 2.A(i)(b), the Intermediate Strain Technology; provided, however, that such obligation shall cease (1) with respect to AMYRIS Licensed IP as of the expiration of the last to expire of the Patents that are included in the AMYRIS Licensed IP at the time of the first commercial sale of a JV 

12

Product or if no such sale has occurred by twenty (20) years after the Effective Date, as of such date, and (2) with respect to the Intermediate Strain Technology upon the existence of (x) a Suitable Commercial Strain or (y) the achievement of a Successful Commercial Transfer of a Commercial Farnesene Strain. 
(vi)    If Company wishes to use any AMYRIS Certification Materials to sell, as certified, a Farnesene Diesel Product or a Farnesene Jet Product, then Company shall notify AMYRIS and shall be obligated to reimburse to AMYRIS for the documented amounts incurred by AMYRIS in generating the applicable AMYRIS Certification Materials after June 21, 2010; provided, however, for activities conducted by AMYRIS Brazil in furtherance of its business in Brazil, no reimbursement shall be required if the Brazil Business has been purchased by or contributed to Company.  Company shall pay such amounts to AMYRIS within thirty (30) days of receipt of an invoice therefor unless otherwise agreed in writing by the Parties.
B.    Third Party Agreements.
(i)    Company acknowledges that certain Patents and/or Inventions within the AMYRIS Licensed IP have been or may be licensed to AMYRIS pursuant to one or more Third Party Agreement(s), and that the sublicenses granted by AMYRIS to Company with respect to the AMYRIS Licensed IP that is subject to any such Third Party Agreement(s) are subordinate to the applicable terms of the applicable Third Party Agreement.  In the event that such terms would impose any obligations on Company beyond those set forth in this Agreement, AMYRIS shall promptly notify Company of such terms of any Third Party Agreement so that Company will be informed of such terms.  If AMYRIS fails to promptly disclose any such terms, then Company shall have no responsibility to comply with the non-disclosed terms or liability for failing to so comply.  In the event that the licenses granted hereunder include a sublicense under the IP License Agreement, the Company acknowledges that such sublicense shall be subject to the Section 2.2 thereof. 
(ii)    Company further acknowledges that, with respect to Patents and/or Inventions within the scope of the AMYRIS Licensed IP or the Intermediate Strain Technology, as applicable, that are licensed pursuant to a Third Party Agreement to AMYRIS or its applicable Affiliate after the completion of the Biofene Development Project, the sublicense granted by AMYRIS to Company may result in payment obligations to the Third Party for the grant and/or practice of such sublicense to Company.  In such a case, with respect to any Third Party Agreement entered by AMYRIS or its Affiliates after the Effective Date, Company shall only receive such a sublicense if it agrees in writing, in a form reasonably acceptable to AMYRIS, to pay any such amounts due for the grant of a sublicense to Company or practice of such a sublicense by Company or its sublicensees (which payments may include milestone payments and/or royalties on product sales), and to otherwise comply with the terms of such Third Party Agreement.
(iii)    In the event of the filing of a bankruptcy petition under Title 11 of the United States Code (the “Bankruptcy Code”) by or against a licensor of intellectual property to AMYRIS under a Third Party Agreement(s) (the “Third Party Licensor”), 

13

AMYRIS hereby assigns to Company the right to make the election set forth in Section 365(n)(1)(B) of the Bankruptcy Code (the “365(n) Election”) if Third Party Licensor as debtor in possession, or a trustee on its behalf, rejects the Third Party Agreement pursuant to Section 365 of the Bankruptcy Code;  provided, however, that such 365(n) Election must be made by Company no later than the earlier of (x) seven (7) Business Days after AMYRIS has provided written notice to Company of any rejection of the Third Party Agreement and (y) five (5) Business Days prior to any date set forth in an order of the bankruptcy court having jurisdiction over the bankruptcy case of Third Party Licensor as the date by which any such Section 365(n) Election must be made, which deadline shall be provided in writing to Company by AMYRIS within two (2) Business Days after AMYRIS receives written notice of same from such Third Party Licensor (the “Election Deadline”).  AMYRIS shall not have the right to make the election set forth in Section 365(n)(1)(A) of the Bankruptcy Code prior to (1) the Election Deadline, in the event Company has timely exercised the 365(n) Election, or (2) if AMYRIS fails to timely notify Company of the rejection of such Third Party Agreement, the date by which such Section 365(n) Election must be made.  If Company does not make the 365(n) Election on or prior to the Election Deadline, then the right to make the Section 365(n) Election shall automatically re-vest in AMYRIS, in which case AMYRIS shall be free to exercise the 365(n) Election in its discretion.  
(iv)    AMYRIS agrees not to terminate or permit termination of the Third Party Agreement containing such license by exercise of an election under Section 365(n)(1)(A) of the Bankruptcy Code without the prior written consent of Company.  AMYRIS acknowledges that because the sublicenses granted by AMYRIS to Company is a significant part of Company’s benefits under the Agreement, Company does not anticipate that it would consent to termination of such Third Agreement and shall not under any circumstances be obliged to give such consent.
(v)    In the event that any royalties are due under a 365(n) Election, then, for clarity, the principles of Section 2.B(ii) shall apply to the allocation of such royalties between the Parties.  For clarity, the allocation between the Parties of any royalties due with respect to the Third Party intellectual property subject to such 365(n) Election shall remain unaltered following such 365(n) Election. 
C.    Sublicenses and Subcontracts.  
(i)    Company shall have the right to grant sublicenses, through multiple tiers, of the licenses granted to Company in Section 2.A; provided, however, with respect to the Manufacture of farnesene, Company may only grant sublicenses for Manufacture of farnesene solely for sale to Company and its other sublicensees to Make and Sell JV Products.  Company and its Affiliates shall bind its sublicensees to the restrictions in clauses (a) and (b) of Section 4.B(iii) and AMYRIS shall have third party beneficiary rights with respect thereto analogous to those set forth in Section 2.C(iii)(b).  
(ii)    Company may grant to a Third Party or TOTAL or any of TOTAL’s Affiliates (any such Third Party, a “Third Party Subcontractor”, and/or to any of Total, 

14

or any of its Affiliates, in its capacity a subcontractor to Company, a “TOTAL Subcontractor”) have made rights under: 
(a) the licenses in Section 2.A(i)(a) and (c), as are reasonably necessary or materially useful to Manufacture the JV Products for, by or on behalf of, Company or Make and Sell JV Products for, by or on behalf of, Company (for clarity, solely for use in the Field), including without limitation, if reasonably necessary or materially useful for the relevant activity, use of the Commercial Farnesene Strain(s), and 
(b) the license in Section 2.A(i)(b), on and after the date on which such license may be practiced, as are reasonably necessary or materially useful to exercise such license, the Intermediate Strain(s).  
Any Subcontractor shall represent, warrant and covenant that its Manufacture and supply of farnesene or the applicable JV Product (or intermediate thereof) to Company will be conducted in accordance with the specifications and instructions provided by Company and all applicable Legal Requirements.
(iii)    Common Provisions.  
(c)    Any sublicense or Subcontractor agreement entered into by Company shall be in writing and contain (1) terms that are consistent in all material respects with this Agreement; (2) reasonable confidentiality terms that obligate the sublicensee or Subcontractor to comply with provisions regarding non-disclosure and non-use of AMYRIS Confidential Information at least as restrictive as those of this Agreement; (3) if the sublicensee or Subcontractor will have access to any Company Strain (such a Person or any other Person that has access to any Company Strain, a “Strain Recipient”), material transfer and use restrictions on the Company Strains consistent with those as described in Section 2.E below, and, without limitation of Section 3.A, such other provisions governing intellectual property as may be agreed in writing by Company and AMYRIS, on a case-by-case basis; (4) a covenant limiting the practice of the licenses to the Field, as described in Section 4.B(iii) below; (5) provisions regarding reporting, audit and inspection rights, including those to protect AMYRIS Farnesene Production IP and the Company Strain(s), including as described in Section 2.F; and (6) provisions to effect the transfer to Company (or at the request of AMYRIS, to AMYRIS) rights to any intellectual property with respect to which AMYRIS is entitled to ownership, as described in Section 3.A hereof).
(d)    Each sublicense or Subcontractor agreement and any other agreement that relates to use of a Strain with a Strain Recipient shall further provide that AMYRIS shall be a third party beneficiary of such agreement by a right to directly enforce against the sublicensee or Subcontractor or other Strain Recipient a material uncured breach of such agreement, as the case may be, if and solely to the extent that (1) such a breach relates to activities conducted with farnesene made by a Company Strain, and (2) Company fails to act reasonably and as expeditiously as possible under the circumstances to address any such breach (provided that such failure to act expeditiously is not the result of any action or inaction on the part of AMYRIS).  For the avoidance of doubt, the foregoing 

15

sentence shall not be deemed to limit any right of any AMYRIS member of the board of directors of Company to act in the best interests of AMYRIS in making any determination as a director.  Each sublicensee of Company hereunder and each Company Affiliate shall also be required to so designate AMYRIS as a third party beneficiary in any of its agreements with any Strain Recipient. 
(e)    Except as otherwise agreed by AMYRIS and Company, each sublicensee and Subcontractor and any other Strain Recipient in any agreement described in clause (b) above shall be required (1) to obtain and maintain insurance at least as great as required to be held by Company pursuant to Section 5.B hereof and (2) to indemnify and hold harmless Company, AMYRIS and TOTAL and their respective directors, officers, employees and agents from and against any and all Third Party claims, suits and proceedings to the extent that such claims, suits and proceedings arise out of, are based on, or result from its willful misconduct or gross negligence or a breach of any provision of Subcontractor’s or sublicensees or Strain Recipient’s agreement with Company (or its Affiliates or sublicensees), including any representation, warranty or covenant thereunder.
D.    Technology Transfer and Escrow.  
(i)    Commercial Technology Transfer.  Following the designation of a Program Strain, to facilitate the practice by Company of the licenses granted herein, at Company’s written request and expense, AMYRIS shall deliver to Company the Program Strain and with regard to the then current process for the Manufacture of JV Products using such Program Strain and the documentation specified on Exhibit B (“Commercial Technology Transfer Package”).  
(ii)    Commercial Strain Technology Transfer Assistance.  At Company's request and expense, to facilitate the practice of the licenses granted to Company, following the designation of the first Program Strain, AMYRIS shall provide to Company (or its designee) a one-time site-specific technology transfer of the then-current Manufacturing process for the JV Products using the Program Strain, which technology transfer shall include training and on-site support (by persons directly involved in the development, use, scale-up and/or operation of the AMYRIS Licensed IP to implement the practice of the AMYRIS Licensed IP and achieve steady state production of farnesene and/or farnesane).  
(iii)    Escrow.  At Company’s expense, AMYRIS will deposit (on the timing specified below) with a mutually agreed Third Party escrow agent (the “Escrow Agent”), pursuant to one or more escrow agreements entered by such Escrow Agent, AMYRIS and Company the following (collectively, the “Escrowed Materials” and each escrowed Strain, a “Banked Strain”): 
(a)    Continuing until the earliest of (1) the existence of a Suitable Commercial Farnesene Strain, (2) the twentieth anniversary of the Effective Date, (3) the termination of the Biofene Development Project prior to the designation of a Program Strain, and (4) the achievement of a Successful Commercial Transfer, AMYRIS shall escrow the following materials:  the Intermediate Strain(s) and the then current process for the Manufacture of JV Products using the Intermediate Strain(s) including the 

16

documentation specified on Exhibit C (“Initial Package”).  The Initial Package shall be escrowed no later than within thirty (30) days of the Effective Date and at least semi-annually thereafter until the occurrence of the earliest of clauses (1) - (4) of this Section 2.D(iii)(a), AMYRIS shall update the Initial Package to reflect the then current process for the Manufacture of JV Products using the then current Intermediate Strain(s). 
(b)    No later than thirty (30) days after designation of each Program Strain, AMYRIS shall escrow the following materials:  such Program Strain and the then current process for the Manufacture of JV Products using such Program Strain, including without limitation, the documentation specified on Exhibit B.  
(c)    Company may, from time to time, obtain access to the Escrowed Materials (at the location of the Escrow Agent) for audit purposes, i.e. to verify that the Escrowed Materials have been properly submitted and stored (provided that if AMYRIS requests, Company’s representative may be accompanied by AMYRIS’ representative during such audit), and upon request of Company and at the Company’s expense, AMYRIS shall cause the Escrowed Materials to be sent to an independent laboratory reasonably agreed to by the Parties to allow testing and to evidence that the Banked Strains remain viable and continue to produce farnesene at expected yields, in which case such laboratory shall be considered a Strain Recipient for purposes of this Agreement.  
(d)    Company will have the right to a release of the Escrowed Materials from the Escrow Agent (1) in the case of the Intermediate Strain(s) and the Initial Package, on or after the date on which the Company has the right to practice the license set forth in Section 2.A(i)(b), or (2) in the case of the Program Strain(s) and the Commercial Technology Transfer Package, if AMYRIS fails to promptly provide the complete technology transfer with respect to the Program Strain contemplated by Section 2.D(ii) or if following such transfer, the Company’s quantity of the Program Strain fails to perform as expected within six (6) months of such transfer.
(e)    AMYRIS’ obligation to escrow the Intermediate Strain(s) and the Initial Package shall terminate as of the achievement of a Successful Interim Transfer and its obligation to escrow the Program Strain(s) and the Commercial Technology Transfer Package shall terminate on the achievement of a Successful Commercial Transfer.  Thereafter, the Company shall be responsible for maintaining the Strains and information that were the subject of the Successful Commercial Transfer.   
(f)    Any dispute between the Parties regarding the deposit of any Escrowed Materials or the access to any Escrowed Materials shall be resolved as provided in Section 8.A, B and D or, if different, the dispute resolution provisions of the Escrow Agreement shall govern and supersede this sentence.   
(iv)    For clarity, the information, know-how and materials disclosed by AMYRIS in any technology transfer or otherwise hereunder shall only be used by Company and its Affiliates and sublicensees and Subcontractors pursuant to the applicable license(s) granted in Section 2.A above and such disclosure is not intended to grant any other rights of use, express or implied.

17

(v)    At the time of delivery of the Initial Package or the Commercial Technology Transfer Package, as the case may be, Amyris shall also provide to the Company, upon its request, the then current capital costs at Amyris’ Brotas plant and its then current operating expenses for farnesene production.
E.    Strain Restrictions.  During the Term except as expressly provided in this Agreement, without the express written consent of AMYRIS, Company shall:
(i)    not and shall not allow any other Person to engage in the further optimization of any Commercial Farnesene Strain(s), including using any strain engineering or method of genetic manipulation by any means other than random mutagenesis, and not to use any other Company Strain other than pursuant to the license set forth in Section 2.A(i)(b), if applicable; 
(ii)    not and shall not allow any other Person to, except as expressly permitted in this Agreement, (a) reverse engineer any Company Strain(s), (b) engineer (other than through random mutagenesis) any other strain from the Commercial Farnesene Strain(s) or engineer any other Company Strain other than pursuant to the license set forth in Section 2.A(i)(b), (c) use any Company Strain, or (d) distribute, disclose or transfer any Company Strain, or any AMYRIS Licensed IP, to any of its Affiliates, TOTAL or any Third Party, with respect to subsections (a) and (b) of this Section 2.E(ii), for any purpose; and with respect to subsections (c) and (d) of this Section 2.E(ii), for any purpose outside of the scope of licenses granted in Section 2.A above and the subcontracting rights set forth in Section 2.C, and in all such cases, such activities shall be subject to the terms of this Agreement;  
(iii)    handle, and cause any Strain Recipient to handle, the Company Strain(s) in a safe and prudent manner, in accordance with applicable law and regulations and guidelines used by AMYRIS in its own activities involving the Company Strains, as provided by AMYRIS to Company;
(iv)    not distribute, disclose or transfer (or permit to be distributed, disclosed or transferred) the Intermediate Strain(s) or any other Strain that is a genetic manipulation or modification of any Intermediate Strain (other than the Commercial Farnesene Strain(s) which the Company may use as described below) in connection with the exercise of its license under Section 2.A(i)(b), if applicable, to any other Person except pursuant to and in accordance with its agreement with Company or to any location other than the following countries:   Australia, Brazil, Canada, Japan, Mexico, South Korea, United States, the countries that are members of the European Union as of the Effective Date, a listing of which is provided on Exhibit E.  For clarity, it is understood and agreed that the Company and its designees may conduct any licensed activities that do not involve the practice of the license granted to Company under Section 2.A(i)(b) (e.g. use of a Commercial Farnesene Strain for production of JV Products as well as any downstream processing of JV Products) in any location such entities deem appropriate;  provided, if the Company or its designees intend to conduct the manufacture of farnesene in any country other than:  Australia, Brazil, Canada, Japan, Mexico, South Korea, United States and the member countries of the European Union which are listed on Exhibit E, the Company shall 

18

notify AMYRIS at least 60 days prior to the selection of the applicable country as a farnesene manufacturing location.  If AMYRIS believes that the farnesene manufacture in such identified country would pose material risk that the conduct of such activities could jeopardize any Commercial Farnesene Strain, including loss of trade secret status with respect to the Commercial Farnesene Strain or any material information with respect thereto or to the related manufacturing process, AMYRIS shall identify such risks with particularity and provide reasonable evidence that the existing precautionary measures provided in this Agreement are insufficient with respect to such material risks.  In any such case, the Parties shall discuss in good faith such risks and other reasonable precautionary measures that could be taken to mitigate such risks.  In the event the Parties agree on such other precautionary measures, then such measures shall constitute the “Precautionary Measures”.  In the event the Parties do not agree on whether any Precautionary Measures should be established or the nature of such Precautionary Measures, either Party may refer the matter to the dispute resolution procedures under Sections 8.A and 8.B for determination of (a) whether any Precautionary Measures should be established and (b) if so, the nature of such Precautionary Measures.  Company shall implement any Precautionary Measures (whether mutually agreed or established pursuant to the preceding sentence) prior to engaging in the licensed activities in the applicable country and shall maintain any such Precautionary Measures in place for so long as such activities are being conducted; and       
(v)    ensure that any sublicensee, Subcontractor or Strain Recipient shall be expressly bound in writing to the provisions set forth in this Section 2.E.   
F.    Reporting, Audit and Inspection Rights.  This Section 2.F shall apply to any Third Party that Manufactures farnesene for Company (each a “Third Party Manufacturer”) or, if the Company Manufactures JV Products itself, to the Company and to any other Strain Recipient.   AMYRIS shall have the right, upon reasonable prior notice and during normal business hours, at agreed times to inspect those portions of facilities at which farnesene is Manufactured or where any Company Strain is used where such activities occur, and the books and records of Third Party Manufacturer or Company or other Strain Recipient, as applicable, relating specifically to such Manufacture or any Company Strain, including any Manufacturing batch records for the Manufacture of farnesene.  At the request of any Third Party Manufacturer, AMYRIS shall enter into a customary confidentiality agreement with the Third Party Manufacturer in form and substance reasonably acceptable to the Manufacturer to keep the results of such inspection confidential, provided that AMYRIS may (i) share with Company the results of any such inspections, and (ii) use and disclose such results to the extent reasonably necessary to enable Company to enforce its rights under its contract with the Third Party Manufacturer. Company or any Third Party Manufacturer, as applicable, shall deliver to AMYRIS a once-monthly summary report relating to any Manufacture conducted using any Company Strain and such other customarily-maintained information regarding such Manufacture as may be reasonably requested by AMYRIS.
G.    No Implied Rights.  For the avoidance of doubt, (i) Company and its Affiliates shall have no right, express or implied, with respect to any intellectual property rights of AMYRIS or any of its Affiliates, except as expressly provided in this Agreement 

19

and (ii) AMYRIS and its Affiliates shall have no right, express or implied, with respect to any intellectual property rights of Company or any of its Affiliates, except as expressly provided in this Agreement.
H.    By-Products.     
(i)     As used in this Section, “Third Party Conflict” is a conflict between (a) a proposed grant of a non-exclusive license to the Company under Section 2.A(i)(d) with respect to a potential Known By-Product or Known By-Product and (b) a written agreement between AMYRIS and a Third Party granting an exclusive license or other exclusive commercial rights (e.g. non-competition) to such Third Party for the applicable potential Known By-Product or Known By-Product for one or more uses, which contractual right is in effect at the time of designation of the applicable By-Product as a Known By-Product, which written agreement either (x) precludes designating such By-Product as a Known By-Product for any uses, or (y) excludes one or more uses from the Company’s non-exclusive license for such Known By-Product(s) for one or more specific uses (including the making of a particular Known By-Product from a non-conflicting By-Product and using such Known By-Product for one or more specific excluded uses).   In the event that a Third Party Conflict exists for some but not all uses for a particular Known By Product, the Third Party Conflict shall only apply to these limited uses. 
(ii)    As used in this Section, a “ Potential Third Party Conflict” is a conflict between (a) a proposed grant of a non-exclusive license to the Company under Section 2.A(i)(d) with respect to any potential Known By-Product or Known By-Product, and (b) any arrangement that AMYRIS is negotiating in good faith with a Third Party pursuant to a written term sheet in which AMYRIS has offered to grant an exclusive license or other exclusive commercial rights (e.g. non competition) with regard to any such By-Products for one or more uses, and timely notified the Company pursuant to Section 2.H(iii) below, provided that such term sheet (whether or not binding) either (x) precludes designating such By-Product as a Known By-Product or (y) specifically excludes one or more uses from the Company’s non-exclusive license for such Known By-Product(s) (including the making of a particular Known By-Product from a non-conflicting By-Product and using such Known By-product for one or more specific excluded uses). If there is a Potential Third Party Conflict, the applicable By-Product shall not be designated as Known By-Product (or in the case of a Known By-Product as of the Effective date, shall be suspended unless and until the first to occur of : (a) AMYRIS ceases such negotiations, or (b) AMYRIS has not completed such negotiations  with the Third Party with which it was negotiating as of the date of AMYRIS’ notice of the Potential Third Party Conflict within twelve (12) months after such receipt or delivery of notice (the “Negotiation Period”).  If AMYRIS timely concludes such negotiations and enters a definitive agreement with such Third Party, then the Potential Third Party Conflict with respect such agreement would become a Third Party Conflict.   In the event that a Third Party Conflict exists for some but not all uses for a particular Known By Product, the Third Party Conflict shall only apply to these limited uses
(iii)   Within three (3) weeks after the Effective Date, AMYRIS shall notify the Company of all Third Party Conflicts with respect to the Known By-Products identified as of the Effective Date and Total, on the behalf of the Company, may, at its election, 

20

initiate the verification process as provided for in Section 2.H.(vii).  With respect to Known By-Products identified as of the Effective Date, AMYRIS shall not enter into any term sheet that would conflict with the rights granted to the Company hereunder and/or any exclusive agreement with any Third Party after the Effective Date.
 (iv)    During the Term of this Agreement, if (x) AMYRIS in the course of performing the Biofene Development Project or (y) the Company identifies any By-Products that are not then Known By-Products, it shall notify the other Party in writing and identify such By-Product (by chemical structure, if possible, and if not, by some other unambiguous manner of characterization) and prevalence relative to the JV Product.   Upon receipt of such notice, such By-Product shall be designated as a Known By-Product (and listed on Exhibit F) unless, within forty-five (45) days of AMYRIS’ receipt or delivery of such notice, AMYRIS notifies the Company of a Third Party Conflict(s) with respect to such By-Product that prevents such By-Product from being designated as a Known By-Product, in which case such By-Product will not be designated as a Known By-Product, except as otherwise provided in this Section 2.H.   
(v)  If AMYRIS fails to identify a Third Party Conflict or Potential Third Party Conflict within the applicable time frame set forth above, with respect to (a) a particular potential Known By-Product, then such potential Known By-Product shall be a Known By-Product and automatically be listed on Exhibit F hereto, and (b) a Known By-Product, then any such unidentified Third Party Conflict shall not limit the Company’s non-exclusive license hereunder with regard thereto.
(vi)  If at any time a Potential Third Party Conflict and/or a Third Party Conflict, as applicable, that previously existed has, in part or in whole, been reduced or eliminated for one or more Known By-Products or for any By-Product denied designation as a Known By-Product, AMYRIS will within thirty (30) days notify the Company in writing, identifying for each By-Product all remaining limitations on such use, and the list of Third Party Conflict(s) will, with regard to such affected By-Products, be automatically modified accordingly.
(vii)    In the event that Company desires verification of the scope or applicability of any Third Party Conflict with respect to any particular Known By-Product or By-Product denied designation as a Known By-Product, then on or after receipt of notice of the applicable Third Party Conflict, the Company shall notify AMYRIS in writing, and AMYRIS shall make available a copy of all terms of the agreement(s) entered by AMYRIS with Third Parties, which terms give rise to the Third Party Conflict(s) at issue, and any ancillary provisions necessary to fully interpret such Third Party Conflict(s), to a mutually acceptable, conflict-free attorney practicing in the United States at a nationally recognized law firm and who has an college or advanced degree in chemistry for the sole purpose of determining whether AMYRIS has accurately described the scope or applicability of the license grant or other restrictions that comprise the Third Party Conflict(s) with regard to the applicable Known By-Product or By-Product denied designation as a Known By-Product so that the Company can be informed of the information described in the following sentence.  Subject to obligations of confidentiality to AMYRIS, such attorney may disclose to the Company, with respect to any particular Known By-Product or By-Product denied 

21

designation as a Known By-Product, the scope of the license(s) and applicable restrictions (including, the uses, geographies and time periods) comprising the Third Party Conflict under the applicable Third Party agreement, but not the provisions themselves.  The costs of any such determination shall be borne by the Company (or its designee) (or, prior to a Go Decision, by Total).
(viii)    In the event that there are limits on the ability of the Company to commercialize a particular Known By-Product or By-Product denied designation as a Known By-Product due to Third Party agreements previously entered by AMYRIS, at the request of the Company, AMYRIS and the Company shall discuss in good faith structures and, if possible, terms for the commercialization of such Known By-Product or By-Product denied designation as a Known By-Product, consistent with AMYRIS’ existing obligations to Third Parties. 
I.    Consequences of Amyris Competitor Control of the Company.  If  an AMYRIS Competitor owns, directly or indirectly, the majority of the Voting Shares of the Company, then as of the effective date of the acquisition of such majority of Voting Shares of the Company (the “Transition Date”), the licenses granted to the Company with respect to (a) AMYRIS Licensed IP, including any AMYRIS Farnesene Production IP, and (b) any Intermediate Strain Technology, shall not include Inventions first made or generated after the Transition Date, or intellectual property rights relating to such Inventions (collectively, the “Excluded Inventions”).  In addition, notwithstanding anything herein, the Company shall have no rights, and AMYRIS shall have no obligations, hereunder with respect to any Excluded Inventions.  

22

ARTICLE 3.    OWNERSHIP AND PATENT MATTERS
A.    Ownership.
(i)    Controlling Terms.  Company acknowledges that (subject to the licenses granted herein) the intellectual property ownership provisions of Section 6.1(d) of the Collaboration Agreement attached as Exhibit D hereto establish the ownership of Collaboration IP and that the terms of Section 6.1 shall govern with respect to any such Collaboration IP; provided, however, that AMYRIS shall be the sole owner of any Inventions that are conceived or reduced to practice by the Company in connection with the exercise of the license grant in Section 2.A(i)(b) and such Inventions shall be considered Collaboration IP.  Company agrees and shall cause its Affiliates (and TOTAL and its Affiliates if TOTAL or any of its Affiliates is a Subcontractor or sublicensee) to agree to intellectual property ownership provisions that allow Company to grant to AMYRIS and TOTAL, respectively, any ownership interest to which they would be entitled under the Collaboration Agreement had the intellectual property been developed by Company itself rather than by such other person or entity.  Company shall use commercially reasonable means to require its other sublicensees and Subcontractors to agree to such provisions.   Any intellectual property developed by a Company Affiliate or sublicensee or any of their respective subcontractors shall be considered developed by the Company for purposes of this provision.  
(ii)    Other Intellectual Property.  Any intellectual property not covered by clause (i) that is developed by or on behalf of the Company shall be owned solely by the Company (or its designee) (unless otherwise agreed by Company and AMYRIS in a written agreement executed after the Effective Date). 
(iii)    Assignment.  In furtherance of the provisions of Section 3.A(i) above, Company hereby assigns, without further consideration, (a) to AMYRIS, all right, title and interest that Company may have from time to time (other than by virtue of the license grants in Section 2 above) in any intellectual property that the Collaboration Agreement allocates sole ownership to AMYRIS, and (b) to AMYRIS and TOTAL, jointly all right, title and interest that Company may have from time to time (other than by virtue of the license grants in Section 2 above) in any intellectual property that the Collaboration Agreement allocates joint ownership to AMYRIS and TOTAL.  AMYRIS hereby assigns to Company, without further consideration, all right, title and interest in any intellectual property in which Company may have any right or interest pursuant to Section 3.A(ii) above.  With respect to Inventions that are the subject of Section 3.A(i) or (ii) above, each Party agrees, at the request and expense of the requesting Party, to execute all documents and take all actions reasonably requested by the other Party from time to time to perfect title to and the ownership interest of the requesting Party in a manner consistent with the allocation of ownership set forth in Section 3.A(i) or (ii), as applicable.
B.    Prosecution and Maintenance of Patents.   
(i)    Collaboration Agreement.  Except as set forth in clause (ii) below, Company agrees that the patent prosecution and maintenance provisions of Section 6.8 of 

23

the Collaboration Agreement apply with respect to the Patents covered thereby and Company agrees to cooperate with all reasonable requests by AMYRIS relating to AMYRIS’ exercise of its rights or performance of its obligations under Section 6.8 of the Collaboration Agreement.  Company shall, at its expense, cooperate fully with AMYRIS in the preparation, filing, prosecution and maintenance of and conducting or defending any interferences, oppositions or similar proceedings with respect to any Patents licensed by AMYRIS to Company under this Agreement or assigned to AMYRIS under this Agreement and in obtaining and maintaining any patent extensions, supplementary protection certificates and the like with respect to any such Patents.  
(ii)    Patent Maintenance.  AMYRIS shall comply with the terms of Section 4.D(i) below.
(iii)    Company-Owned Patents.  Company shall at its discretion and expense, conduct and be responsible for the prosecution and maintenance of patent applications and Patents owned by it.  To the extent that AMYRIS is involved in the conception or reduction to practice of any Inventions owned by Company hereunder, AMYRIS shall, at Company’s expense, cooperate fully with Company in the preparation, filing, prosecution and maintenance of and conducting or defending any interferences, oppositions or similar proceedings with respect to any Patents filed with respect to such Inventions and in obtaining and maintaining any patent extensions, supplementary protection certificates and the like with respect to any such Patents.
C.    Information Rights. 
(i)    Status Reports.   Following (a) execution of the common interest agreement contemplated in Section 3.F and (b) the commencement of the Operational Phase, AMYRIS shall provide to the Company at least quarterly, or on such other schedule as the Parties may agree, a status report on the prosecution and maintenance of patent applications and patents within the AMYRIS Licensed IP.  In addition, AMYRIS shall provide Company with periodic updates regarding Inventions (including intellectual property) generated in connection with the Biofene Development Project and/or that specifically relate to JV Products, decisions to file (or not file) patent applications with respect to such Inventions, and the status of any patent applications filed with respect to such Inventions. 
(ii)    Review Rights.  To allow the Company to be informed with respect to AMYRIS Licensed IP licensed to Company under this Agreement, Company shall have the right, on reasonable notice, to inspect and review the following records maintained by AMYRIS relating to the information contained in those certain Biofene Development Project weekly reports and quarterly reports provided under the Collaboration Agreement and the associated documentation forming the basis of such reports, including at least, standard operating protocols, procedures, batch records, reports regarding deviations, laboratory notes, bioinformatic and genomic data, detailed fermentation performance data in the laboratory, pilot plant or manufacturing runs, in each case, solely to the extent necessary (or in the case of the AMYRIS Farnesene Production IP included therein, materially useful) for Company (or its sublicensees or Subcontractors) to exercise its rights 

24

or perform its obligations under this Agreement and, for clarity, provided that AMYRIS shall not be required to create any documents not already in existence for the sole purpose of complying with this clause 3.C(ii). 
D.    Patent Enforcement.  
(i)    Notice.  Each of AMYRIS and Company shall promptly notify the other in writing of any existing or threatened infringement or misappropriation by any Third Party of any AMYRIS Licensed IP licensed to Company under this Agreement, which infringement or misappropriation could reasonably be expected to have a material adverse effect on the ability of the Company or its designees to Make and/or Sell one or more JV Products (“Infringement”) of which it becomes aware, and upon reasonable request (and subject to an applicable common interest agreement) shall provide all evidence in its possession demonstrating such Infringement (other than information that such Party is prevented from disclosing due to confidentiality or other similar obligations). 
(ii)    Collaboration Agreement.  Company agrees that the patent enforcement provisions of Section 7.2 of the Collaboration Agreement shall govern the intellectual property that is the subject thereof and agrees to be bound by such provisions, except as expressly provided below.
(a)    AMYRIS.  AMYRIS shall have the first right (but not the obligation) to enforce any issued patent(s) within the AMYRIS Licensed IP claiming the use of any JV Product(s) in the Field, including without limitation (1) US Patent No. 7,399,323 and/or US Patent No. 7,846,222 (and any foreign equivalents), and/or (2) any issued Patent that is within the AMYRIS Licensed IP and comprises Collaboration IP developed by or on behalf of Company, in each case, against any Third Party infringement (including any declaratory judgment with respect to Third Party non-infringement) that would adversely affect the business of Company relating to JV Products in the Field and to conduct the defense in connection with any such action.  At the request of AMYRIS or Company, Company and AMYRIS shall discuss means to cease any such infringement.  If AMYRIS fails to commence a proceeding to cease any such infringement within one hundred twenty (120) days of becoming aware of such an infringement, Company shall have the right to commence and control proceedings to cease any such infringement.  In each case, the enforcing Party may retain any damages recovered in any such proceeding.  In any enforcement proceeding that is the subject of this Section 3.D(ii)(a), Company (and its Affiliates and sublicensees) or AMYRIS, as the case may be, shall join in any such proceeding, at the enforcing Party's request or if required by applicable law, in each case at the enforcing Party’s expense.  In a case in which Company is enforcing under this Section 3.D(ii)(a), AMYRIS and Company shall seek to develop a litigation strategy that will cease the infringement while limiting any adverse impact on the other businesses of AMYRIS or any of its Affiliates or licensees.   
(b)    Company.  For any Patents or other intellectual property owned by Company, Company shall have the sole right, at its expense, to enforce and defend such Patents or other intellectual property (including without limitation, any declaratory judgment actions) and to retain any recovery.

25

(c)    Cooperation.  In connection with any claim, suit or proceeding subject to this Section 3.D (including per Section 7.2 of the Collaboration Agreement), the Parties shall cooperate with each other (in the case of enforcement by Company, at the expense of Company) and shall keep each other reasonably informed of all material developments in connection with any such claim, suit or proceeding.  
(d)    Settlement.  In connection with any claim, suit or proceeding subject to this Section 3.D(ii), neither Party shall enter into any settlement agreement with any Third Party that would conflict with rights granted to the other Party under this Agreement, or impose any obligations on such other Party (beyond those already included herein), without the prior written consent of such affected Party, which consent shall not be unreasonably withheld.
E.    Infringement of Third Party Rights.  
(i)    If a JV Product becomes the subject of a claim or assertion of infringement of a Third Party Patent granted in any jurisdiction, the Party first learning of such claim or assertion shall promptly notify the other Party in writing, and shall provide all information relating thereto (other than information that such Party is prevented from disclosing due to confidentiality or other similar obligations). 
(ii)    In the event of such a Third Party claim of infringement, any Party that is the subject of such claim or assertion under this Section 3.E may defend itself in its sole discretion and at its sole expense; provided, however, that (a) the Party that is the indemnifying Party with respect to such claim pursuant to the terms of Section 5 or (b) the Party designated in writing by the Parties may control the conduct of any proceeding and in such case the procedures set forth in Section 5.A shall govern the defense of such action.  In any such case, the Indemnified Party shall cooperate with the Indemnifying Party with such defense; provided, if there is a conflict of interest between the Parties, the Indemnified Party shall be entitled to be represented by separate counsel at the Indemnifying Party’s expense.  In a case in which Company is defending an action under this Section 3.E(ii)(b), AMYRIS and Company shall seek to develop a litigation strategy to defend the claim while limiting any adverse impact on the other businesses of AMYRIS or any of its Affiliates or other licensees. 
(iii)    In connection with any such claim of infringement, Company and AMYRIS shall cooperate in the defense of any such action at the request and expense of the party controlling such action, unless there is a material conflict of interest that would prevent such cooperation. 
(iv)    In connection with any claim, suit or proceeding that is the subject of this Section 3.E, neither Party shall enter into any settlement agreement with any Third Party that would conflict with rights granted to the other Party under this Agreement, or impose any obligations on such other Party (beyond those already included herein), without the prior written consent of such affected Party, which consent shall not be unreasonably withheld.  

26

F.    Common Interest Disclosures and Agreement. With regard to any information, materials or opinions disclosed relating to the freedom to operate under the licenses granted hereunder, which information, materials or opinions are regarding intellectual property or technology owned by Third Parties that may affect the conduct of Company and the activities contemplated by this Agreement, the Parties agree that they have a common legal interest in determining whether, and to what extent, such Third Party intellectual property rights may affect the conduct of Company and the activities contemplated by this Agreement, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights relating to Company.  All such information, materials and opinions will be treated if applicable as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity from discovery that may otherwise be applicable.  By sharing any such information, materials or opinions, neither Party intends to waive or limit any privilege or immunity from discovery that may apply to the shared information and materials.  Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party’s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against the other Party.  In addition, with regard to (i) the prosecution of Patents for intellectual property developed by or on behalf the Company and governed by the Collaboration Agreement and (ii) other relevant matters, the Parties shall enter into (with TOTAL) a reasonable common interest agreement, with the consent to the terms not to be unreasonably withheld. 
ARTICLE 4.    REPRESENTATIONS, WARRANTIES AND COVENANTS
A.    Mutual Representations and Warranties.  Company hereby makes the following representations and warranties to AMYRIS, and AMYRIS hereby makes the following representations and warranties to Company, in each case as of the Effective Date:
(i)    It is a company duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized.  It has all requisite corporate power and authority to own its respective properties and to carry on its respective business as conducted as of the date of this Agreement and as proposed to be conducted.    It has the requisite power and authority to execute, deliver and perform its obligations under this Agreement.
(ii)    All corporate action on the part of it, its officers, directors and stockholders necessary for the authorization, execution and delivery of this Agreement, and the performance of all obligations hereunder, has been taken or shall be taken prior to the date of this Agreement, and this Agreement, when executed and delivered by it, shall constitute a valid and legally binding obligation of it, enforceable against it in accordance with its terms except to the extent that (a) such enforcement may be subject to bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect relating to creditor’s rights generally and (b) the remedy of specific performance or injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.

27

(iii)    The execution, delivery and performance of this Agreement (with or without the giving of notice, the lapse of time or both) and the consummation of the transactions contemplated hereby, (a) do not require the consent of any Third Party; (b) do not conflict with, result in a breach of, or constitute a default under, its organizational documents or any other material contract or agreement to which it is a party or by which it may be bound or affected; and (c) do not violate in any material respect any provision of applicable law or any order, injunction, judgment or decree of any Governmental Entity by which it may be bound, or require any regulatory filings or other actions to comply with the requirements of applicable law, except to the extent that either Party is required to file any notification pursuant to applicable anti-trust or competition laws.  It is not a party to, nor is it bound by, any agreement or commitment that prohibits the execution and delivery of this Agreement.
(iv)    No insolvency proceedings of any character, including bankruptcy, receivership, reorganization, composition or arrangement with creditors, voluntary or involuntary, affecting it are pending or threatened, and it has not made any assignment for the benefit of creditors or taken any action in contemplation of, or which would constitute the basis for, the institution of such insolvency proceedings.
(v)    There is no action, suit, proceeding or investigation pending or threatened against it which questions the validity of this Agreement.  It is not in violation of any applicable law in respect of the conduct of its business or the ownership of its properties which violation would have a material adverse effect on its business or the ownership of its properties, and it shall undertake its obligations hereunder in accordance in all material respects with applicable law.
B.    Covenants of Company.  During the Term: 
(i)    Company and its Affiliates shall have valid arrangements with all of its consultants and employees that are enforceable in accordance with its terms, except as enforcement may be limited or affected by applicable bankruptcy, insolvency, moratorium, reorganization or other laws of general application relating to or affecting creditors’ rights generally, and are sufficient to assign all of their rights, title and interest in and to all Inventions or other technology or intellectual property developed or created by them to Company or its Affiliates, as applicable, in order to effect the ownership principles set forth in Section 3.A. 
(ii)    Company shall not enter into any agreement, contract, lease, license, instrument or other arrangement with a Third Party that results in a breach of or constitutes a default under this Agreement.
(iii)    Company and its Affiliates and sublicensees shall not (a) exercise the licenses granted in Section 2.A outside the Field, or (b) knowingly sell JV Products to customers for use outside the Field.
(iv)    Company shall not, and shall use reasonable efforts to ensure that its sublicensees and customers do not, use or sell any JV Product for any use outside the Field.

28

C.    Representations and Warranties of AMYRIS.  AMYRIS represents and warrants, as of the Effective Date, that:  
(i)    AMYRIS and/or its Affiliates (a) owns and possesses sufficient right, title and interest in the AMYRIS Licensed IP to grant the rights granted herein, (b) has a valid and enforceable written license to the AMYRIS Licensed IP that includes the right to sublicense to the extent of the licenses granted herein and/or (c) has obtained all necessary consents of any Third Party required, for AMYRIS and/or any of its Affiliates to grant the licenses and sublicenses to Company with respect to the AMYRIS Licensed IP granted herein.
(ii)    The non-financial terms of this Agreement are no less favorable than those licenses that AMYRIS grants to other partners for the Manufacture of farnesene and/or farnesane.
(iii)    As of the Effective Date, AMYRIS has provided to Company an accurate and complete list of all existing agreements between AMYRIS (and/or its Affiliates) and Third Parties that provide to AMYRIS (and/or its Affiliates) licenses or other rights to AMYRIS Licensed IP that AMYRIS believes may be necessary for the practice of the AMYRIS Licensed IP by the Company with respect to the JV Products under the licenses granted in Section 2.A(i)(a) and (c), and has disclosed to the Company all terms in such agreements that would impose any obligations on Company beyond those set forth in this Agreement. 
(iv)    The AMYRIS Licensed IP is subject to no Liens and/or other restrictions and/or limitations, in each case which would prevent the grant to Company of the licenses set forth herein on the terms and conditions set forth herein, and neither AMYRIS nor any of its Affiliates has granted any Third Party any rights under the AMYRIS Licensed IP or the Intermediate Strain Technology in the Field that would conflict with the licenses granted to the Company herein.
(v)    Neither AMYRIS nor any of its Affiliates is in material breach of any of its agreements with Third Parties and no Third Party has notified AMYRIS and/or any of its Affiliates of any material breach of such Third Party Agreement(s), in each case that remains uncured and which would result in a material adverse effect on the ability of AMYRIS and/or its Affiliates to perform its obligations hereunder.  AMYRIS and/or its Affiliates have not received written notice from any licensor under a Third Party Agreement purporting to terminate, and/or restrict the scope of, AMYRIS' rights under such Third Party Agreement by reason of any action and/or omission of AMYRIS and/or its Affiliates.
(vi)    Except as provided by AMYRIS to TOTAL prior to the Effective Date, AMYRIS and its Affiliates (a) have not received any communications alleging that any use of the AMYRIS Licensed IP by AMYRIS or any of its Affiliates has violated, infringed or misappropriated or would violate, infringe or misappropriate any of the intellectual property of any other person or entity and (b) has no Knowledge of any Third Party infringement, misappropriation or violation of any AMYRIS Licensed IP.  

29

(vii)    to its Knowledge, there are no pending or issued patent rights of any Third Party that foreclose practice of any AMYRIS Licensed IP for the following purposes:  (a) to make farnesene using the Mevalonate Pathway or (b) to Make and Sell JV Products. 
(viii)    Novvi, per Section 5.2 of the IP License Agreement, has (a) agreed that AMYRIS and/or its Affiliates solely and exclusively own the AMYRIS Biofene Manufacturing Technology and (b) has assigned exclusively to AMYRIS all rights, title, and interest in and to any and all inventions, discoveries, data and information, whether or not copyrightable or patentable, conceived, reduced to practice, made, observed or developed (together with all intellectual property rights related thereto) by or on behalf of Novvi or its Affiliates or sublicensees, solely or jointly with others, or jointly by or on behalf of AMYRIS and Novvi (or their respective Affiliates, employees, sublicensees, contractors, or agents), in each case that are based upon, derived from, incorporating, in connection with, or related to the Amyris Biofene Manufacturing Technology.  The “AMYRIS Biofene Manufacturing Technology” are patents and know-how that are controlled by AMYRIS and are necessary or reasonably useful for the development, making (and having made), offering for sale, sale, and importing of farnesene itself, including, but not limited to, Farnesene Strains and any patents and know-how related to the genetic engineering of such Farnesene Strains, the fermentation methods for making farnesene, the methods of recovery of farnesene from fermentation broth, the processes of isolating farnesene directly from fermentation broth, and the methods of purifying farnesene. 
(ix)    To its Knowledge, other than that certain notice of opposition set forth on Schedule 4.C(ix) (a) there is no claim by any Person contesting the validity and/or enforceability of the Patents within the AMYRIS Licensed IP, and/or use and/or ownership of the AMYRIS Licensed IP, is currently outstanding and/or threatened, and (b) there is no pending (i.e., filed and/or requested) interference and/or litigation that involves any of the Patents within the AMYRIS Licensed IP licensed hereunder.
D.    AMYRIS' Covenants.  AMYRIS hereby covenants that during the Term:  
(i)    AMYRIS and its Affiliates shall timely pay all maintenance costs, annuity payments and similar fees due with respect to all Patents within the AMYRIS Licensed IP issued in the following countries:  United States, Europe (in any country(ies) where any European Patent was validated), Brazil, Canada, China, India, and Japan.  AMYRIS shall notify Company prior to abandoning any other issued Patents within the AMYRIS Licensed IP with respect to which Company has an enforcement right pursuant to Section 3.D and afford Company an opportunity to pay the maintenance fees and annuity payments associated with such Patents and if the Company makes such payments, AMYRIS and each of its Affiliates shall promptly assign to the Company its entire right, title and interest in such Patent.  AMYRIS shall notify Company if any Patents within the AMYRIS Licensed IP become subject to an interference, reissue, or re-examination.  In such event, if AMYRIS elects not to undertake commercially reasonable efforts to respond to such interference, reissue or re-examination and defend the claims at issue, then it shall notify Company and afford Company the right to respond thereto.   Notwithstanding the foregoing, Company’s rights with respect to prosecution under this clause (i) shall apply with respect to in-licensed AMYRIS Licensed IP only to the extent that AMYRIS has the 

30

right to afford the Company such rights, e.g., AMYRIS controls prosecution of the applicable patent applications or patent rights under the applicable license agreement.
(ii)    For so long as any Third Party Agreement is necessary or materially useful for Company to Make and Sell the JV Products using a Commercial Farnesene Strain (“Subject Third Party Agreement”), (a) with respect to Subject Third Party Agreements that are necessary for Company to (x) practice the licenses in Section 2.A(i)(a) or (c) or (y) practice the licenses in Section 2.A(i)(b), AMYRIS shall, and shall cause each of its Affiliates to, comply with all of its obligations under the Subject Third Party Agreements and will not terminate or amend such Subject Third Party Agreement in each case in any manner which diminishes the licenses to Company or increases any obligations of Company with respect to the AMYRIS Licensed IP that is subject to such Subject Third Party Agreement (“Detriment”) without the consent of Company and (b) with respect to Subject Third Party Agreements that are materially useful for Company to (x) practice the licenses in Section 2.A(i)(a) or (c), or (y) practice the licenses in Section 2.A(i)(b), AMYRIS shall provide advance written notice to Company in connection with terminating or amending such Subject Third Party Agreement that would result in a Detriment.  In addition, AMYRIS will, and will cause each of its Affiliates to, notify Company promptly, if AMYRIS and/or any of its Affiliates receives notice, whether or not there is a cure period, from a Third Party that AMYRIS and/or any of its Affiliates and/or other licensees is in material breach of any such Subject Third Party Agreement if such material breach could result in a Detriment, and/or notice from any Third Party which purports to modify and/or terminate any such Subject Third Party Agreement in a manner that would cause a Detriment.  AMYRIS will and will cause its Affiliates to take prompt and commercially reasonable steps to cure any such breach.  AMYRIS acknowledges that any breach of such Subject Third Party Agreement(s) by AMYRIS and/or its Affiliates may result in damage to Company with respect to the subject AMYRIS Licensed IP, which may include loss of license rights to such AMYRIS Licensed IP and/or monetary damages.  For any Subject Third Party Agreement entered into by AMYRIS after the Effective Date that satisfies the criteria above, AMYRIS agrees that it will use commercially reasonable efforts to obtain an agreement from the licensor that Company can continue with its sublicense if the license to AMYRIS under the applicable Subject Third Party Agreement is terminated, that Company may approach AMYRIS' licensors under the Subject Third Party Agreements for the limited purpose of obtaining an agreement from such a licensor that Company can continue with it sublicense if the license to AMYRIS under the applicable Subject Third Party Agreement is terminated, and AMYRIS agrees that it shall facilitate such contact, on Company's request, and AMYRIS will not object to such an agreement.
(iii)     AMYRIS shall not enter into any agreement, contract, lease, license, instrument or other arrangement with a Third Party that results in a breach of or constitutes a default under this Agreement or that would conflict with the licenses and rights granted to the Company hereunder. 
(iv)    No member of the AMYRIS Family other than a Third Party Acquirer shall commercialize, or grant any Third Party any rights to commercialize, any isoprenoid or isoprenoid-derived compound for a Diesel Product or Jet Product or otherwise conduct or authorize any activity in conflict with the licenses granted in Section 

31

2, provided that the exercise of its retained rights hereunder as set forth in Section 2.A(iv) above shall not be construed as a violation of this clause (iv).  
(v)    Company shall not be obligated to pay to AMYRIS any fees of any type (including royalties, milestones, maintenance, sublicense, etc.) beyond any amounts due under Section 2.A(iii) or (vi) or Section 2.B for its use, license, sublicense and/or any other commercial exploitation of the licenses granted Company herein with respect to the AMYRIS Licensed IP.
(vi)    AMYRIS shall promptly inform Company if AMYRIS and/or any of its Affiliates becomes aware of any action, suit, investigation and/or proceeding pending and/or threatened before any arbitrator and/or any governmental authority, in each case, to which AMYRIS or any of its Affiliates is a party, which could reasonably be expected to have a material adverse effect on the ability of Company and/or any of its Affiliates to practice any of the rights granted Company in this Agreement.
(vii)    Until the expiration or termination of the Collaboration Agreement, AMYRIS shall not, without prior notice to Company, enter into any grant or contract that may provide any government or non-for profit entity any rights (e.g., rights provided to the U.S. Government under 35 U.S. 200 et seq. or any similar provisions of foreign law) to any patent application or patents resulting from work done in connection with such grant or contract that would be materially useful in connection with the conduct of the Biofene Development Project or to Manufacture farnesene to make JV Products or to Make and Sell JV Products.  
(viii)    AMYRIS shall not, and shall not permit any Affiliate to, create, incur, assume or permit to exist any Lien on any Invention within the AMYRIS Licensed IP owned by AMYRIS or its Affiliates as of the Effective Date or hereafter acquired; provided, however, that AMYRIS and its Affiliates shall not be precluded by this clause (viii) from granting licenses to its Affiliates and Third Parties under the AMYRIS Licensed IP, provided that such licenses do not conflict with the licenses and other rights granted to the Company hereunder.  For clarity, nothing in this clause (viii) shall restrict the granting by AMYRIS of (a) licenses with respect to products other than JV Products,  (b) licenses outside the Field or (c) licenses within the scope of AMYRIS’ retained rights under Section 2.A(iv).  
(ix)    AMYRIS shall not, and shall not permit any Affiliate to, use any Known By-Product to Make or Sell any JV Product except in connection with the Brazil Business.  
(x)    AMYRIS shall not amend the terms of the Amended and Restated NOVVI Side Letter with regard to its prohibition on the sale of certain NOVVI by-products for certain uses or AMYRIS’ obligation to buy certain NOVVI by-products in any manner that may adversely affect the Company, without the express prior written consent of the Company.  
(xi)    In the event that the Company or AMYRIS become aware that Novvi LLC has breached the Amended and Restated NOVVI Side Letter, it shall notify the other providing detailed information.  In the event that NOVVI breaches the Amended and 

32

Restated NOVVI Side Letter, AMYRIS, upon Company’s written request, agrees to use its best efforts to enforce the Amended and Restated NOVVI Side Letter against NOVVI including, if necessary, promptly commencing legal action against NOVVI to cease such breach and recover damages for such breach.   
(xii)    AMYRIS shall not, and shall not assist (by joining as a party or otherwise) any Third Party to, commence or conduct any legal action against the Company or its Sublicensees or Subcontractors for the production of any By-Products in compliance with the terms of this Agreement.
E.    Disclaimer.  EXCEPT AS PROVIDED IN THIS ARTICLE 4, NEITHER PARTY MAKES ANY WARRANTIES TO THE OTHER, WHETHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AS TO ANY PRODUCT OR PROCESS, OR AS TO THE VALIDITY OR SCOPE OF ANY OF INTELLECTUAL PROPERTY OR THAT THE PRACTICE OF ANY OF INTELLECTUAL PROPERTY WILL BE FREE FROM INFRINGEMENT OF ANY PATENT OR OTHER PROPRIETARY RIGHT OF ANY THIRD PARTY OR TOTAL OR ANY OF ITS AFFILIATES.  
ARTICLE 5.    INDEMNITY; LIMITATION OF LIABILITY  
A.    Indemnification.
(i)    Indemnification by Company.  Company shall defend, indemnify, and hold AMYRIS and AMYRIS’ officers, directors, employees, and agents (the “AMYRIS Indemnitees”) harmless from and against any and all damages, liabilities, judgments, recoveries, costs, and expenses (including court costs and reasonable attorneys’ fees and expenses), resulting from any claims, suits, actions or proceedings of any Third Party (collectively, “Claims”) to the extent that such Claims arise out of, are based on, or result from (a) a breach of any of Company’s representations, warranties, covenants and/or obligations under this Agreement; (b) the willful misconduct or grossly negligent acts of Company or its Affiliates, or the officers, directors, employees, or agents of Company or its Affiliates in connection with its activities under this Agreement; or (c) the exercise by Company of the licenses granted hereunder (excluding claims for infringement and misappropriation of a Third Party’s intellectual property for which AMYRIS is obligated to indemnify Company pursuant to Section 5(A)(ii)(b) below); in each case except to the extent such Claims arise out of, are based on, or result from (x) a breach by AMYRIS of any of AMYRIS’ representations, warranties, covenants and/or obligations under this Agreement; or (y) the willful misconduct or grossly negligent acts of AMYRIS, its Affiliates, or the officers, directors, employees, or agents of AMYRIS or its Affiliates.    
(ii)    Indemnification by AMYRIS.  AMYRIS shall defend, indemnify, and hold Company and its Affiliates and each of their officers, directors, employees, and agents (the “Company Indemnitees”) harmless from and against any and all damages, liabilities, judgments, recoveries, costs, and expenses (including court costs and reasonable attorneys’ fees and expenses), resulting from any Claims (as defined in Section 5.A(i) 

33

above) to the extent that (A) such Claims arise out of, are based on, or result from (a) a breach of any of AMYRIS’ representations, warranties, covenants and/or obligations under this Agreement, (b) any manufacture by the Company of farnesene that allegedly has infringed or misappropriated a Third Party’s intellectual property, but only to the extent such alleged infringement or misappropriation is directly attributable to Company’s adherence to AMYRIS’ then approved farnesene manufacturing process (as provided in the Successful Commercial Transfer) licensed from AMYRIS as part of the AMYRIS Licensed IP and not to any deviation or modification from such process made by or on behalf of Company other than a deviation or modification made by Company at the written direction of AMYRIS, (c) the willful misconduct or grossly negligent acts of AMYRIS, its Affiliates, or the officers, directors, employees, or agents of Company or its Affiliates or (B) such Claims (a) are Patent infringement claims brought by Novvi against the Company, (b) allege that one or more of the JV Products infringes one or more Patents owned by Novvi and (c) are based on Inventions conceived and reduced to practice by Novvi; in each case ((A) and (B)), except to the extent such Claims arise out of, are based on, or result from (x) a breach by Company of any of Company’s representations, warranties, covenants and/or obligations under this Agreement; or (y) the willful misconduct or grossly negligent acts of Company and its Affiliates or the officers, directors, employees, or agents of Company or its Affiliates.  
(iii)    Indemnification Procedures.  In the event that a Party claiming indemnity under this Section 5.A (the “Indemnified Party”) becomes aware of any Claim for which it seeks indemnification from the other Party (the “Indemnifying Party”), the Indemnified Party shall: (a) reasonably promptly notify Indemnifying Party thereof, in no event later than ten (10) business days after the Indemnified Party becomes aware of such Claim (provided that failure to provide such notice will not release the Indemnifying Party from any of its indemnity obligations hereunder except to the extent that such failure increases the Indemnifying Party's indemnity obligation); (b) permit the Indemnifying Party to assume control of the defense or settlement of the Claim; (c) at the Indemnifying Party’s expense, provide the Indemnifying Party with reasonable cooperation in the defense or settlement thereof; and (d) not settle any such claim without the Indemnifying Party’s written consent, not to be unreasonably withheld.  The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense.  If the Indemnifying Party does not assume and conduct the defense of the claim as provided above, (x) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (y) the Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Section 5.A.
B.    Insurance.  Prior to the commencement of its operational activities, Company shall acquire, and thereafter maintain, product liability insurance and general commercial liability insurance, to the extent, in amounts and from carriers with quality ratings not lower than industry standards for a similarly situated company, during the Term and thereafter for so long as Company is exercising its license rights granted hereunder and including with respect to Company’s facilities used in conducting such activities.  

34

Company shall provide to AMYRIS a certificate of insurance evidencing such coverage upon request.  
C.    Limitation of Liability.  EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES OR WITH RESPECT TO A BREACH OF ARTICLE 6, NEITHER PARTY, NOR ANY OF ITS AFFILIATES, SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER.  FOR CLARITY, ANY DAMAGES FINALLY AND ACTUALLY SUFFERED BY AN INDEMNIFIED PARTY (WHETHER BY A FINAL JUDGMENT OF A COURT OF LAW OR THROUGH A SETTLEMENT) ARISING OUT OF A CLAIM FOR WHICH THE INDEMNIFIED PARTY IS INDEMNIFIABLE UNDER THIS ARTICLE 5 SHALL BE DEEMED DIRECT DAMAGES FOR PURPOSE OF THIS SECTION 5.C.  NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY PUNITIVE DAMAGES HEREUNDER. 
ARTICLE 6.    CONFIDENTIALITY
A.    Confidential Information.  Except to the extent expressly authorized by this Agreement or otherwise provided herein or agreed in writing by the Parties, during the Term and for two (2) years thereafter, each Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as permitted in this Agreement, the Collaboration Agreement, or the Related Agreements, any Inventions or other confidential information, including any information relating to any Strain, disclosed to it by the other Party or its Affiliates pursuant to this Agreement (collectively, “Confidential Information” of the disclosing Party).  Each Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own, but in no event less than reasonable care, to ensure that its and its Affiliates’ and sublicensees’ employees, previous employees, agents, consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information of the other Party.  Each Party shall promptly notify the other upon discovery of any unauthorized use or disclosure of the other Party’s Confidential Information.  The terms and conditions of this Agreement (but not the existence hereof) shall be the Confidential Information of both Parties.  Any Confidential Information disclosed hereunder shall be the Confidential Information of the disclosing Party.  The receiving Party is permitted to use such Confidential Information only to the extent permitted in this Agreement, the Collaboration Agreement or the Related Agreements.  Any Inventions owned by AMYRIS under this Agreement (including by reference to the Collaboration Agreement in Section 3.A above) shall constitute Confidential Information of AMYRIS.  Any Inventions jointly owned by AMYRIS and TOTAL or any Affiliate of TOTAL for purposes of this Agreement shall constitute Confidential Information of AMYRIS.  The Parties acknowledge that under the Collaboration Agreement, such jointly owned Inventions and any Inventions solely owned by TOTAL under this Agreement (including by reference to the Collaboration Agreement in Section 3.A above) constitute TOTAL’s Confidential Information (as defined therein) and under the TOTAL License Agreement (as defined in the Company’s Shareholder 

35

Agreement) if and when executed may also be considered TOTAL’s Confidential Information (as defined therein).    
B.    Exceptions.  The obligations of non-disclosure and non-use under Section 6.A shall not apply to any Confidential Information of a disclosing Party if the receiving Party can prove by contemporaneous written documentation or otherwise reasonably demonstrate that such Confidential Information: (1) is at the time of receipt, or thereafter becomes, through no breach of this Agreement by the receiving Party, generally known or publicly available; (2) is known by the receiving Party at the time of receiving such Confidential Information; (3) is hereafter furnished to the receiving Party by a Third Party, which is not, to the receiving Party’s reasonable knowledge, in breach of any confidentiality obligation related to such information; (4) is independently discovered or developed (in the case of the Company, without the practice of the licenses granted hereunder or reference to the AMYRIS Licensed IP or the Confidential Information of AMYRIS, and without use of Confidential Information of AMYRIS under the Collaboration Agreement and without violation of any agreement between AMYRIS and any of its Affiliates, on the one hand, and TOTAL or any of its Affiliates, on the other hand), (5) is the subject of a written permission to disclose provided by the disclosing Party; or (6) is disclosed pursuant to any ruling of a governmental or regulatory authority or court or by mandatory law, provided that written notice of such ruling is given, as soon as reasonably possible, to the disclosing Party so as to give the disclosing Party an opportunity to intervene and provided further that the receiving Party uses reasonable efforts to obtain assurance that the Confidential Information shall be treated confidentially.  In addition, each Party may disclose Confidential Information of the other Party to the extent such disclosure is reasonably necessary in the following instances:  
(i)    filing or prosecuting Patents as permitted by this Agreement;
(ii)    regulatory filings for products to which such Party has a license or a right to develop hereunder; 
(iii)    prosecuting or defending litigation as permitted by or relating to this Agreement; 
(iv)    otherwise required by law or the requirements of a national securities exchange or other similar regulatory body; provided that the receiving Party shall (a) provide the disclosing Party with reasonable advance notice of, and an opportunity to comment on, any such required disclosure, to the extent such advance notice is legally permitted, (b) if requested by the disclosing Party, and at the disclosing Party’s expense, seek confidential treatment with respect to any such disclosure to the extent available, and (c) use good faith efforts to incorporate the comments of the disclosing Party in any such disclosure or request for confidential treatment;
(v)    complying with applicable Legal Requirements or governmental requests;
(vi)    disclosure to its Affiliates, licensees, sublicensees and Subcontractors and their respective representatives, who reasonably need to know such 

36

Confidential Information for the purpose of performing the obligations or exercising its license rights as described in this Agreement and internal reporting to its Affiliates, provided, in each case, each Party shall be responsible for ensuring that all such representatives to whom the Confidential Information is disclosed under this Agreement shall keep such information confidential and shall not disclose the same to any unauthorized person; or
(vii)    to underwriters or investors or potential investors or their counsel or accountants in connection with a Monetization (as defined in Section 13.6 of the Collaboration Agreement) or other investment transaction (and to its and their respective Affiliates, Representatives and financing sources); provided, however, that each such Third Party to whom information is disclosed will (a) be subject to obligations of confidentiality substantially similar hereunder, (b) be informed of the confidential nature of the Confidential Information so disclosed, and (c) agree to hold such Confidential Information subject to the terms thereof; provided, that the disclosure rights shall not apply with respect to the other Party’s intellectual property.
C.    Public Disclosures of Technical Information.  If Company seeks to publish any technical information relating to any Strain, the substance of which  has not been previously approved by AMYRIS for publication or disclosure, Company shall first provide to AMYRIS the material proposed for disclosure or publication, such as by oral presentation, manuscript or abstract, and AMYRIS shall have the right to review and comment on all such material.  Before any such material is submitted for publication, Company shall deliver a complete copy to AMYRIS at least sixty (60) days prior to submitting the material to a publisher or initiating any other disclosure.  AMYRIS shall review any such material and give its comments to Company as soon as practicable, but no later than forty-five (45) days after delivery of such material to Company.  Company shall not publish any such technical information, the substance of which has not been previously approved by AMYRIS for publication or disclosure, without AMYRIS’ prior written consent in each instance, which consent shall not be unreasonably withheld or delayed. For clarity, such consent is not required for disclosures relating to the JV Products to the extent such disclosure does not comprise technical information relating to Strains.
D.    Publicity and Disclosure of this Agreement.  A Party that desires to make, or that is required to make pursuant to applicable laws or regulations, any press release or other public disclosure regarding the existence or terms of this  Agreement (including the identity of the other Party to this Agreement) shall first consult with the other Party (to the extent such consultation does not violate applicable laws or regulations) with respect to the text and timing of such press release or other public disclosure and shall obtain the other Party’s approval over the text and timing of such release and disclosure prior to the issuance or disclosure thereof (to the extent such approval does not violate applicable laws or regulations).  Following the initial press release or other public disclosure announcing the existence or terms of this Agreement (if any), each Party shall be free to disclose, without the other Party’s prior written consent, the existence of this Agreement, the identity of the other Party and those terms of this Agreement which have already been publicly disclosed in accordance herewith.

37

E.    Residuals.  Nothing in this Agreement shall restrict any employee or representative of a Party from using general ideas, concepts, practices, learning, or know-how relating to any activities conducted on behalf of the Company (“General Know-How”) that are retained in the unaided memory of such employee or representative following performance of the Biofene Development Project and such employee or representative is not aware at the time of use that such information is Confidential Information of the other Party, provided that the foregoing is not intended to grant, and shall not be deemed to grant (i) any right to disclose the Confidential Information of the other Party, or (ii) any license under any Patents of the other Party.  The General Know-How shall in no event include any financial, business statistical, or personnel information specific to the other Party.  A person’s memory is “unaided” if such person has not intentionally memorized the Confidential Information for the purpose of retaining and subsequently using or disclosing it otherwise than as authorized pursuant to this Agreement.
ARTICLE 7.    TERM AND TERMINATION
A.    Term.  The term of this Agreement shall commence on the Effective Date and remain in effect for fifty (50) years unless there is a No-Go Decision for both JV Products, in which case this Agreement shall automatically terminate as described in 7.B(i) (the “Term”).
B.    Consequence of Events.  The Parties agree as follows:
(i)    No Go Decision.  In the case of a No-Go Decision by TOTAL as to both JV Products, this Agreement and licenses granted herein shall automatically terminate immediately.
(ii)    Jet Go Decision.  In the case of a Jet Go Decision, JV Product shall include only (a) farnesene or farnesane for use in Jet Product and (b) Farnesane Jet Product and the Field thereafter shall no longer include diesel fuel applications but Farnesane Jet Product shall continue to be a JV Product.   
(iii)    Buy-Out Closing.  For clarity, this Agreement shall remain in full force and effect in the event of any Buy-Out Closing.
(iv)    Change of Control of AMYRIS.  For clarity, this Agreement shall remain in full force and effect in the event of any Change of Control of AMYRIS.     
(v)    Termination of Collaboration Agreement.  For clarity, the Parties agree that, regardless of any termination of the Collaboration Agreement, this Agreement shall remain in full force and effect accordingly to its terms.
C.    Termination of Agreement.   
(i)    The licenses granted to the Company herein shall be irrevocable (other than as specified in Section 7.B or this Section 7.C), provided in the case of  a material breach (but only in the case of a material breach) of the relevant license, AMYRIS 

38

shall have a right to terminate the applicable license in accordance with the following.  If AMYRIS believes any such breach by the Company has occurred, AMYRIS shall within thirty (30) days provide written notice to Company describing the specific alleged material breach.  If a material breach is not cured within ninety (90) days of the Company’s receipt of such notice, then AMYRIS may terminate the applicable license with further written notice to Company (A) immediately at the end of such ninety (90) day period, if the Company has not contested the allegation, or (B) if the Company has contested such allegation, only upon a final written determination, if any, of an arbitrator in a proceeding subject to Section 8.B that a material uncured breach has occurred.  For clarity, in the case of any dispute between the Parties as to whether any uncured material breach has occurred that would permit AMYRIS to terminate a license or this Agreement, no notice of termination may be given and no such termination shall be effective until the final resolution of a dispute resolution proceeding conducted pursuant to Section 8.B, and such licenses may only be terminated if the arbitrator finally determines a material uncured breach has occurred.
(ii)    In the case of an uncured material breach of Section 2.E(i) or (ii) by the Company, then, except to the extent Section 7.C(iii) below applies, AMYRIS shall have the right to terminate the licenses granted in Section 2.A in their entirety in accordance with the procedure described in Section 7.C (i) above, and in the case of such a license termination, this Agreement shall terminate concurrently.  
(iii)    In the case of any uncured material breach by the Company based on the use of any Intermediate Strain or any other Strain that is a genetic manipulation or modification of any Intermediate Strain  (other than any Commercial Farnesene Strain(s)) outside the scope of the limited license in Section 2.A(i)(b), then in accordance with the procedure described in clause 7.C (i) above, AMYRIS shall have the right to terminate the license granted in Section 2.A(i)(b) and all other rights of Company permitting its development and use of Intermediate Strains, including Company’s right to release of the Escrowed Materials relating to the Intermediate Strains) as described in clause (i) above but AMYRIS may not otherwise terminate any provision of this Agreement or this Agreement in its entirety.    
(iv)    For purposes of determining whether a material breach that would trigger a right of termination under Section 7.C has occurred, any Affiliate of the Company shall be treated as if it was the Company.  
(v)    Except as expressly provided in this Section 7.C(v), no acts or omissions of any Subcontractor or sublicensee of the Company shall be the basis of any termination of this Agreement.  In the event that any Subcontractor or sublicensee of Company violates Section 2.E(i) or Section 2.E(ii)(a) or (b), then such violation may provide a basis for a material breach and termination of this Agreement under clause 7.C(ii) above, but only if the Company fails to use commercially reasonable efforts to cure such breach, which efforts may include terminating its agreement with such Subcontractor or sublicensee and initiating and continuing to pursue appropriate legal action to stop such unauthorized activity.  In the event that a sublicensee or Subcontractor of Company uses any Intermediate Strain in a manner that exceeds the scope of or violates the restrictions on 

39

the exercise of the license in Section 2.A(i)(b), then in accordance with the procedure described in Section 7.C (i) above, AMYRIS shall have the right to terminate the license in Section 2.A(i)(b) pursuant to Section 7.C(iii) and Company’s related rights in respect of Intermediate Strains but only if the Company is not using commercially reasonable efforts to cure such breach, which efforts may include terminating its agreement with Affiliate, sublicensee or subcontractor pertaining to the Intermediate Strain(s) and initiating and continuing to pursue appropriate legal action to stop such unauthorized activity.    
D.    Conversion to Non-Exclusive License.  In the event of the expiration of this Agreement at the end of the Term, the Company shall retain a perpetual, non-exclusive (subject to Section 2.A(iv)), royalty-free (subject to Section 2.A(iii) and (vi) and Section 2.B) right and license under the AMYRIS Licensed IP, in each case that is necessary or, in the case of the AMYRIS Farnesene Production IP, useful to Make and Sell JV Products within the Territory.
E.    Effects of Termination.
1.    Strains; Return or Destruction of Confidential Information.  Except as provided in Section 7.D, upon expiration or termination of this Agreement and/or the licenses granted herein, as applicable, Company shall immediately cease and cause its Affiliates, sublicensees and Subcontractors to cease use of any AMYRIS Licensed IP, Intermediate Strain Technology and all Company Strains (or in the case of a termination under Section 7.C(iii), the Intermediate Strains and any Strains derived therefrom) and within ninety (90) days following a written request from the other Party, each receiving Party shall at the disclosing Party’s discretion, promptly destroy or return to the disclosing Party (a) all written copies of the disclosing Party’s Confidential Information that is marked confidential and (b) all biological materials (including all Company Strains), in each case (a) and (b) to which the receiving Party does not retain rights hereunder, except that the receiving Party may retain such Confidential Information or materials, to the extent that the receiving Party requires such Confidential Information or materials for the purpose of performing any obligations under this Agreement that may survive such expiration or termination, or with respect to Confidential Information only for archival purposes or for information contained in management reports.  In the case of (i) a Jet Go Decision, the foregoing obligations in this Section 7.E(1) shall apply with respect to Inventions, Confidential Information and, if applicable, Company Strains relating solely to the Diesel Product and not the Jet Product and (ii) a Jet Go Decision followed by expiration or termination of this Agreement, the foregoing obligations in this Section 7.E(1) shall apply with respect to all Inventions, Confidential Information and, if applicable, Company Strains. 
2.    Rights in Bankruptcy.  All rights and licenses granted under or pursuant to this Agreement to the Company are, and will otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code (the “Bankruptcy Code”), licenses of rights to “intellectual property” as that term is defined in the Bankruptcy Code.  Company, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code.  Upon the filing of a case by or against AMYRIS or any AMYRIS Affiliate (the “Bankrupt Entity”), including 

40

without limitation, AMYRIS Fuels LLC, AB Technologies LLC, and/or AMYRIS Brasil Ltda. (each of such Affiliates, a “Co-Licensor”) under the Bankruptcy Code, then (a) Company shall be entitled to the fullest protections conferred upon licensees under Section 365(n) of the Bankruptcy Code, or any similar provision; (b) AMYRIS and each Co-Licensor shall perform all of its obligations under this Agreement; (c) the Bankrupt Entity shall immediately, without the need for any further request by Company, or notice or hearing, provide to Company  a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property (which embodiments, throughout this Agreement, shall include without limitation, the Escrowed Materials), or any other information necessary or desirable for Company to utilize such intellectual property; and (d) AMYRIS and each Co-Licensor shall not interfere with the rights of Company as provided in this Agreement, or in any agreement supplementary to this Agreement, to such intellectual property (including such embodiment), including any right to obtain such intellectual property (and such embodiment) from another entity or person.  To the extent AMYRIS and/or a Co-Licensor rejects this Agreement under the Bankruptcy Code and Company elects to retain its rights, (x) Company shall have the full rights provided to it under Section 365(n) of the Bankruptcy Code; (y) the waivers under Section 365(n)(2)(C) shall apply only to rights of setoff and administrative claims arising solely out of this Agreement, and not to any other agreements or instruments, including, without limitation, claims or rights arising out of agreements supplementary to this Agreement; and (z) the Bankrupt Entity shall, without need for notice or hearing, provide to Company any intellectual property (including such embodiment) held by AMYRIS and/or each Co-licensor and/or any other entity or person, and shall not interfere with the rights of Company as provided in this Agreement, or any agreement supplementary to this Agreement, to such intellectual property (including such embodiment) including any right to obtain such intellectual property (and such embodiment) from another entity or person.   For purposes of this Agreement, the term “embodiment” shall mean any and all materials required to be delivered by AMYRIS or a Co-Licensor to Company hereunder and any materials relating to the licenses granted hereunder  which, in the course of dealing between the Parties under this Agreement, are customarily delivered, in whatever format (whether electronic, written or otherwise).   All written agreements entered into relating to and in connection with the Parties’ performance hereunder from time-to-time, shall be considered agreements “supplementary” to this Agreement for purposes of Section 365(n) of the Bankruptcy Code.  AMYRIS and each Co-Licensor acknowledges and agrees that the rights of Company to such intellectual property (and such embodiments) are unique, and that to the extent AMYRIS or a Co-Licensor, or their respective trustees in bankruptcy, were to sell any portion of such intellectual property free and clear of liens, claims or interests, Company would suffer irreparable damages, such that AMYRIS and each Co-Licensor agrees that such sale shall not occur without Company’s express written consent.  For the avoidance of doubt, “intellectual property,” as used in this Section 7.E.2, is limited to intellectual property included in the AMYRIS Licensed IP and the Intermediate Strain Technology, and any tangible embodiments of such intellectual property, and includes all such intellectual property and tangible embodiments of such intellectual property (provided in the case of the Intermediate Strain Technology, only to the extent, and for the uses and period, described in Section 2.A.(i)(b)).    

41

3.    Accrued Rights.  Termination or expiration of this Agreement for any reason shall not release either Party from any liability or obligation that already has accrued prior to such expiration or termination, nor affect the survival of any provision hereof to the extent it is expressly stated to survive such termination.  Termination or expiration of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims, whether for damages or otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination or expiration.  
F.    Survival.  Subject to the other provisions set forth in this Article 7 and any other applicable terms and conditions of this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration of this Agreement:  Articles 1 (Definitions) (to the extent any definitions are applicable after termination or expiration hereof), 5 (Indemnity; Limitation of Liability), 6 (Confidentiality) (for the period set forth therein), 8 (Dispute Resolution) and 9 (Miscellaneous); Sections 2.A (License to Make and Sell JV Products) (where the licenses are on the non-exclusive basis described above), 2.B (Third Party Agreements), 2.C (Sublicenses and Subcontracts), 2.E (Strain Restrictions), 2.F (Reporting, Audit and Inspection Rights), 2.G (No Implied Rights), 2.I, 3.A (Ownership), 3.E (Infringement of Third Party Rights), 3.F (Common Interest Disclosures and Agreement), 4.E (Disclaimer), 7.C (Termination of Agreement), 7.D (Conversion to Non-Exclusive License) and 7.E (Effects of Termination); and this Section 7.F (Survival).  Subject to the other provisions set forth in this Article 7 and any other applicable terms and conditions of this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive termination of this Agreement:  Articles 1 (Definitions) (to the extent any definitions are applicable after termination or expiration hereof), 5 (Indemnity; Limitation of Liability), 6 (Confidentiality) (for the period set forth therein), 8 (Dispute Resolution) and 9 (Miscellaneous); Sections 3.A (Ownership), 3.E (Infringement of Third Party Rights), 3.F (Common Interest Disclosures and Agreement), 4.E (Disclaimer), 7.C (Termination of Agreement) and 7.E (Effects of Termination); and this Section 7.F (Survival). 
ARTICLE 8.    DISPUTE RESOLUTION
A.    Escalation.  Except as provided in Section 8.B or 8.D, if any Dispute arises between the Parties under this Agreement, such Dispute shall be referred to the Executive Officers for further discussion and resolution.  The Executive Officers shall attempt in good faith to resolve any Dispute referred to it pursuant to this Section 8.A within ten (10) days after such referral by meeting (either in person or by video teleconference, unless otherwise mutually agreed) at a mutually acceptable time, and thereafter as often as they reasonably deem necessary, to exchange relevant information and to attempt to resolve the Dispute.  If the Dispute has not been resolved within twenty (20) days thereafter and the Dispute does not consist of a failure by the Parties to reach agreement where one or both Parties have discretion whether to agree, either Party may, by written notice to the other Party, elect to initiate arbitration pursuant to Section 8.B for purposes of having the Dispute and any related Disputes resolved.  If an Executive Officer intends to be accompanied at a meeting by an attorney, the other Executive Officer shall be given at least forty-eight (48) hours’ notice of such intention and may also be accompanied by an attorney.  All negotiations 

42

conducted pursuant to Section 8.B, and all documents and information exchanged by the Parties in furtherance of such negotiations, (i) are the Confidential Information of the Parties, (ii) shall be treated as evidence of compromise and settlement for purposes of the United States Federal Rules of Evidence and any other applicable state or national rules of evidence or procedure, and (iii) shall be inadmissible in any arbitration conducted pursuant to this Section 8 or other proceeding with respect to a Dispute. 
B.    Arbitration.  Except for Disputes that are subject to Sections 8.C, D or E, all Disputes arising out of or in connection with this Agreement that cannot be resolved by the Executive Officers pursuant to Section 8.A shall be finally settled as follows: 
(i)    Except for Disputes that are subject to Section 8.C, D or E, all Disputes arising out of or in connection with this Agreement that cannot be resolved by the Executive Officers pursuant to Section 8.A, shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce (the “ICC Rules”) by an arbitration tribunal appointed in accordance with the said ICC Rules as modified hereby.
(ii)    There shall be three (3) arbitrators, one selected by the initiating Party in the request for arbitration, the second selected by the other Party within twenty (20) days of receipt of the request for arbitration, and the third (who shall act as chairperson of the arbitration tribunal) selected by the two (2) Party-appointed arbitrators within twenty (20) days of the selection of the second arbitrator.  In the event that the respondent fails to select an arbitrator, or if the two Party-appointed arbitrators are unable or fail to agree upon the third arbitrator, the international Court of Arbitration of the International Chamber of Commerce shall designate the remaining arbitrator(s) required to comprise the tribunal. The claimant in the arbitration shall provide a copy of the request for arbitration to the respondent at the time such request is submitted to the Secretariat of the International Chamber of Commerce.
(iii)    Each arbitrator chosen under this Section shall speak, read, and write English fluently and shall be either (a) a practicing lawyer who has specialized in business litigation with at least ten (10) years of experience in a law firm of over fifty (50) lawyers or (b) a retired judge of a court of general jurisdiction.
(iv)    The place of arbitration shall be New York, New York. The language of the arbitral proceedings and of all submissions and written evidence shall be English; provided, however, that a Party, at its expense, may provide for translation or simultaneous interpretation into a language other than English.
(v)    The arbitrators shall issue an award within nine (9) months of the submission of the request for arbitration. This time limit may be extended by agreement of the Parties or by the tribunal if necessary.
(vi)    It is expressly understood and agreed by the Parties that the rulings and award of the tribunal shall be conclusive on the Parties, their successors and permitted assigns. Judgment on the award rendered by the tribunal may be entered in any court having jurisdiction thereof.

43

(vii)    Each Party shall bear its own costs and expenses and attorneys' fees, and the Party that does not prevail in the arbitration proceeding shall pay the arbitrator's fees and any administrative fees of arbitration.  All proceedings and decisions of the tribunal shall be deemed Confidential Information of each of the Parties, and shall be subject to Article 6.       
For clarity, any disputes between the Parties regarding the deposit of Escrowed Materials or access to any Escrowed Materials shall not be required to be resolved via arbitration, and either Party may seek equitable relief for such dispute, including without limitation, specific performance, pursuant to Section 8.D.
C.    Patent Validity and Infringement Disputes.  In the event that a Dispute arises with respect to the inventorship, scope, validity, enforceability, revocation or infringement of a Patent, and such Dispute cannot be resolved by the Executive Officers in accordance with Section 8.A, unless otherwise agreed by the Parties in writing, such Dispute shall not be submitted to arbitration in accordance with Section 8.B, and notwithstanding anything in this Agreement to the contrary, the sole forum to resolve such Dispute shall be to initiate litigation in a court or other tribunal of competent jurisdiction in the country of issuance of the Patent that is the subject of the Dispute.  
D.    Equitable Relief.  Notwithstanding anything to the contrary, either Party may at any time seek to obtain equitable relief from a court of competent jurisdiction with respect to an issue arising under this Agreement if the rights of such Party would be prejudiced absent such relief.  
E.    Disputes Subject to Section 2.A(iii).  In the event of any disagreement between the Parties (or their successors) regarding the terms on which any Inventions subject to Section 2.A(iii) shall be licensed to Company, then at the request of Company (or its successor), such dispute be resolved by a single arbitrator agreed by the Parties or if the Parties are unable to agree within thirty (30) days of Company’s request, selected by the head of the New York office of the International Chamber of Commerce.  Such arbitrator shall have expertise in the licensing of biotechnology intellectual property for industrial applications.  Each Party shall submit to the arbitrator a written brief of its position regarding the license terms, which submission (including supporting documentation) shall not exceed 50 pages.  The arbitrator shall select the position of one of the Parties, in its entirety, as his or her decision, and shall have no authority to vary any of the terms of the prevailing proposal. The Parties shall equally share the costs of such arbitration.  Any such arbitration shall be completed within 120 days of selection of the arbitrator.
F.    Attorney’s Fees.  If any action, proceeding or arbitration is brought by a Party to enforce or interpret this Agreement, the prevailing Party, in addition to all other legal or equitable remedies possessed, shall be entitled to be reimbursed for all reasonable attorneys’ fees incurred by reason of such action or proceeding to the extent related to the enforcement or interpretation of this Agreement.  

44

ARTICLE 9.    MISCELLANEOUS
A.    Governing Law.  This Agreement and any arbitration hereunder shall be governed by, interpreted and construed and enforced in accordance with, the laws of the State of New York, without giving effect to any conflicts of laws principles thereof. 
B.    Entire Agreement; Modification.  This Agreement, together with the Company’s Articles of Association until the Buy-Out Closing, and the Related Agreements to which both AMYRIS  and Company are parties, constitutes the entire agreement of the Parties with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral, among the Parties with respect to the subject matter hereof.  No warranty, representation, inducement, promise, understanding or condition not set forth in this Agreement has been made or relied upon by either Party with respect to the subject matter of this Agreement.  No rights or licenses with respect to any intellectual property right of either Party are granted or deemed granted hereunder or in connection herewith, other than those rights expressly granted in this Agreement.  This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement.  For clarity, the Collaboration Agreement remains in full force and effect. 
C.    Relationship.  This Agreement establishes between the Parties an independent relationship.  While this Agreement is entered into as part of the Related Agreements relating to the establishment of Company and its operations, the Parties intend that no partnership or joint venture is created hereby between Company and AMYRIS, that neither Party will be a partner or joint venturer of the other Party for any purposes, and that this Agreement will not be construed to the contrary. 
D.    Non-Waiver.  Either Party may (i) extend the time for the performance of any of the obligations or other acts of the other Party, (ii) waive any inaccuracies in the representations and warranties of the other Party contained herein or in any document delivered by the other Party pursuant hereto, or (iii) waive compliance with any of the agreements or conditions of the other Party contained herein.  Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the Parties.  Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition, of this Agreement.  The failure of either Party to assert any of its rights hereunder shall not constitute a waiver of any of such rights.  Any extension of time or other indulgence granted to a Party hereunder shall not otherwise alter or affect any power, remedy or right of the other Party or the obligations of the Party to whom such extension or indulgence is granted.
E.    Assignment.  This Agreement may not be assigned by either Party without the express written consent of the other Party; provided, however, that either Party may assign its rights and obligations pursuant to this Agreement without the written consent of the other Party to any of its Affiliates; provided, that (i) such Affiliate agrees to be bound by the terms of this Agreement, and (ii) Company may not assign this Agreement to any AMYRIS Competitor without the written consent of AMYRIS.  In the event of any Buy-

45

Out Closing, notwithstanding the foregoing, this Agreement shall thereafter (a) be assignable by Company to an AMYRIS Competitor that is an Affiliate of TOTAL without the consent of AMYRIS; and (b) be assignable by AMYRIS to a Third Party in connection with a Change of Control of AMYRIS.  Any purported assignment not specifically described above shall be null and void, without the express written agreement of both Parties hereto.   
F.    Severability.  If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any applicable law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect to the fullest extent permitted by law.  Upon determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a reasonably acceptable manner.
G.    Notices.  Any notice to be given under this Agreement must be in writing and delivered either in person by registered or certified mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of (a) the date of actual receipt; (b) if mailed, three (3) days after the date of postmark; or (c) if delivered by overnight courier, the next business day the overnight courier regularly makes deliveries.
If to Company, notices must be addressed to:
Claude Debussylaan 24
1082 MD 
Amsterdam, the Netherlands
With a required copy to (which shall not constitute notice):
Total Energies Nouvelles Activités USA        24 Cours Michelet        92800 Puteaux        France        Attn:      [*[, President        Fax. No.:  +[*]        Email:    [*]
If to AMYRIS, notices must be addressed to:

AMYRIS, Inc.
5885 Hollis Street, Suite 100
Emeryville, CA 94608
Attention: General Counsel
Facsimile: [*]

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

46

H.    Force Majeure.  Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party’s reasonable control including but not limited to acts of God, fire, flood, explosion, earthquake, or other natural forces, war, civil unrest, accident, any strike or labor disturbance, or any other event similar to those enumerated above.  Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur and continues to use diligent, good faith efforts to avoid the effects of such event and to perform the obligation.  Notice of a Party’s failure or delay in performance due to force majeure must be given to the unaffected Party promptly thereafter but no later than five (5) days after its occurrence which notice shall describe the force majeure event and the actions taken to minimize the impact thereof.  All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure.  In no event shall any Party be required to prevent or settle any labor disturbance or dispute.   
I.    Trademarks and Logos.  Neither Party shall use, in advertising or otherwise, the other Party’s or its Affiliates’ names, trade names, trademarks, service marks, logos or other indicia of origin or refer to the other Party or its Affiliates, directly or indirectly, in any media release, public announcement or public disclosure relating to this Agreement or its subject matter, including in any promotional or marketing materials, lists, referral lists, or business presentations, without prior written consent from the other Party for each such use or release.  The restrictions imposed by this Section 9.I shall not prohibit either Party from making any disclosure (a) identifying the other Party as a counterparty to this Agreement to its or its Affiliates’ actual or prospective acquirers, merger candidates, underwriters, or investors (and their attorneys and accountants), (b) that is required by Applicable Law or the requirements of a national securities exchange or another similar regulatory body (provided that any such disclosure shall be governed by Section 6) or (c) with respect to which written consent of the other Party has previously been obtained.
J.    Export Control.  Notwithstanding anything to the contrary contained herein, all obligations of the Parties are subject to prior compliance with export regulations applicable to each Party and such other related laws and regulations as may be applicable to each Party, and to obtaining all necessary approvals required by the applicable government entity. Each Party shall each use its reasonable efforts to obtain such approvals for its own activities. Each Party shall cooperate with the other Parties and shall provide assistance to the other Parties as reasonably necessary to obtain any required approvals.  
K.    Interpretation.
(i)    Captions & Headings.  The captions and headings of clauses contained in this Agreement preceding the text of the articles, sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. 
(ii)    Singular & Plural.  All references in this Agreement to the singular shall include the plural where applicable, and all references to gender shall include both 

47

genders and the neuter. 
(iii)    Including as Example.  Use of the term “including” or “include” in this Agreement shall be interpreted to mean “including, without limitation,” or “include, but not limited to,” and shall be exemplary rather than restrictive.   
(iv)    Sections & Subsections.  Unless otherwise specified, references in this Agreement to any section shall include all subsections and paragraphs in such sections, and references in this Agreement to any subsection shall include all paragraphs in such subsection. 
(v)    Days.  All references to days in this Agreement mean calendar days, unless otherwise specified. 
(vi)    Ambiguities.  Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. 
(vii)    English Language.  All notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement shall be in the English language. 
L.    Drafting.  Each Party agrees that it participated equally with the other in the drafting of this Agreement, using counsel of its choice. This Agreement shall be interpreted without regard to any principle of construction regarding the drafting, authorship or revision thereof.
M.    Further Assurances.  After the Effective Date, each of the Parties shall execute and deliver such additional documents, certificates, and instruments and perform such additional acts, as may be reasonably requested and necessary or appropriate to carry out the purposes and intent and all of the provisions of this License Agreement and to consummate all of the transactions contemplated by this License Agreement. 
N.    License Registrations.  Company may, at its expense, register the exclusive licenses granted under this Agreement in any country of, or community or association of countries in, the Territory.  AMYRIS shall reasonably cooperate in such registration at Company’s expense.  Upon request by Company, AMYRIS agrees promptly to execute any "short form" licenses developed in a form reasonably acceptable to both Company and AMYRIS and reasonably submitted to it by Company from time to time in order to effect the foregoing registration in such country.  No such "short form" license shall be deemed to amend or be used to interpret this Agreement.  If there is any conflict between such a license or other recordation document and this Agreement, this Agreement shall control. 
O.    Counterparts.  This Agreement and any amendments hereto may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each Party and delivered to the other Party, it being understood that both Parties need not sign the same counterpart.  Any such counterpart, to the extent delivered by electronic delivery, 

48

shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.  Neither Party shall raise the use of electronic delivery to deliver a signature, or the fact that any signature or agreement or instrument was transmitted or communicated through the use of electronic delivery, as a defense to the formation of a contract, and each Party forever waives any such defense, except to the extent such defense relates to lack of authenticity.
P.    Affiliates.  Each Party hereto shall be responsible for ensuring that its Affiliates (whether existing as of the Effective Date or thereafter during the term of this Agreement) comply with the terms of this Agreement. 
[Signatures on following page]

49

THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written above.

	
									
	AMYRIS, Inc.
	 
	Company

	By:
	               /s/
	 
	By:
	 

	Name:
	John Melo
	 
	Name:
	 

	Title:
	  C.E.O.
	 
	Title:
	 

The following AMYRIS Affiliates existing as of the Effective Date of this Agreement hereby acknowledge and approve the licenses granted to Company in Section 2.A and Section 7.E.2 of this Agreement.  

	
				
	AMYRIS Fuels LLC

	By:
	          /s/

	Name:
	NICHOLAS S. KHADDER

	Title:
	SECRETARY

	AB Technologies LLC

	By:
	          /s/

	Name:
	NICHOLAS S. KHADDER

	Title:
	PRESIDENT

	AMYRIS Brasil Ltda.

	By:
	 

	Name:
	 

	Title:
	 

THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written above.

	
									
	AMYRIS, Inc.
	 
	Company

	By:
	 
	 
	By:
	                     /s/                   /s/

	Name:
	 
	 
	Name:
	OTERO DEL VAL   JOHN G. MELO

	Title:
	 
	 
	Title:
	                                       MANAGING DIRECTOR

The following AMYRIS Affiliates existing as of the Effective Date of this Agreement hereby acknowledge and approve the licenses granted to Company in Section 2.A and Section 7.E.2 of this Agreement.  

	
				
	AMYRIS Fuels LLC

	By:
	 

	Name:
	 

	Title:
	 

	AB Technologies LLC

	By:
	 

	Name:
	 

	Title:
	 

	AMYRIS Brasil Ltda.

	By:
	 

	Name:
	 

	Title:
	 

THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written above.

	
									
	AMYRIS, Inc.
	 
	Company

	By:
	 
	 
	By:
	 

	Name:
	 
	 
	Name:
	 

	Title:
	 
	 
	Title:
	 

The following AMYRIS Affiliates existing as of the Effective Date of this Agreement hereby acknowledge and approve the licenses granted to Company in Section 2.A and Section 7.E.2 of this Agreement.  

	
				
	AMYRIS Fuels LLC

	By:
	 

	Name:
	 

	Title:
	 

	AB Technologies LLC

	By:
	 

	Name:
	 

	Title:
	 

	AMYRIS Brasil Ltda.

	By:
	               /s/

	Name:
	Paulo Diniz

	Title:
	President

	By:
	              /s/

	Name:
	Erica Baumgartner

	Title:
	AB  CFO

	
	
	Schedule 4.C(ix)

A Notice of Opposition was filed by Maiwald Patentanwalts GMBH on February 21, 2013 against European Patent EP1778831 granted on May 23, 2012.

Exhibit A
Brazil Business terms
 (copy of Article 4 of Amended and Restated Master Framework Agreement)

4.1   Rights to Conduct the Brazil Business.
(i)    The “Brazil Business” shall mean production and commercialization of Farnesane Diesel Products and Farnesane Jet Products within Brazil for commercialization solely in Brazil. The Brazil Business shall include the right to produce Farnesane Diesel Products and Farnesane Jet Products outside of Brazil for commercialization within Brazil, but shall exclude the right to produce Farnesane Diesel Products and Farnesane Jet Products within Brazil for commercialization outside of Brazil (it being understood that the commercialization of Farnesane Diesel Products and Farnesane Jet Products for use in vehicles which begin an international travel segment within Brazil and conclude such international travel segment outside of Brazil shall constitute commercialization of such products within Brazil).
(ii)    The parties acknowledge that it would be desirable for the Brazil Business to be conducted by a single entity. Accordingly, (i) if the Brazil Business is contributed to JVCO pursuant to Section 4.3, then JVCO shall be entitled to conduct the Brazil Business exclusively and independently of Amyris and Total; and (ii) if the Brazil Business is acquired by Total pursuant to Section 4.2 or Section 4.4, Total shall be entitled to conduct the Brazil Business exclusively and independently of Amyris and JVCO. If the Brazil Business is not contributed to JVCO or acquired by Total pursuant to the preceding sentence, the parties shall use reasonable best efforts to agree on a single entity to commercialize Farnesane Diesel Products and Farnesane Jet Products in Brazil, provided, that in the event the parties are unable to agree, Amyris shall be entitled to conduct the Brazil Business independently of Total and JVCO. Promptly following the occurrence of a Go Decision or a Jet Go Decision, Amyris agrees to provide Total and JVCO with complete and accurate information to allow each Advisor, Total and/or JVCO, as applicable, to accurately and independently estimate the value of the Brazil Business. Amyris shall promptly provide all requested information. In connection with the preceding sentence, Amyris shall provide each Advisor, Total, JVCO and their respective advisors with reasonable access during normal business hours, upon reasonable notice, to any assets, properties, contracts, books, records and personnel of the Brazil Business as they may reasonably request. In the event that Total shall make a Jet Go Decision, Amyris and Total shall work together in good faith to evaluate the feasibility of restructuring the Brazil Business to separate the assets of the Brazil Business related to the development, production and commercialization of Farnesane Diesel Products from the assets of the Brazil Business related to the development, production and commercialization of Farnesane Jet Products.
4.2   Sale of Brazil Business to Total Prior to Final Go Decision Date.

A-1

(iii)    If, prior to the Final Go Decision Date, Total acquires all of the common and preferred equity interests in JVCO other than pursuant to an Amyris Change of Control, then Total shall have an option to acquire the Brazil Business at the Brazil Business Fair Market Value. To exercise this option, Total shall deliver written notice to Amyris within 90 days following its acquisition of all of the common and preferred equity interests in JVCO that it intends to commence the process of establishing the Brazil Business Fair Market Value and shall deliver written notice to Amyris of its exercise of such option within 30 days following the determination of the Brazil Business Fair Market Value. If Total has exercised such option, then within 60 days following the delivery of such notice to Amyris (i) Total shall pay to Amyris, by wire transfer to an account in the United States designated by Amyris, an amount equal to the Brazil Business Fair Market Value; and (ii) Amyris will sell the Brazil Business to Total, which sale shall be effected by such documents as, in the reasonable opinion of Total, are necessary or appropriate to convey the Brazil Business to Total; provided, that Amyris shall be required to provide customary representations and warranties agreed to by the parties for this kind of transaction, including, without limitation, basic representations and warranties regarding its authority to enter into the sale documentation, the due execution and binding nature of the sale documentation by Amyris, and that its participation in the sale will not contravene, or require a consent, waiver or approval pursuant to, any applicable law or pursuant to any agreement to which it is subject. If the Brazil Business is to be transferred to Total pursuant to this Section 4.2, each of the parties shall use its reasonable best efforts to take, or cause to be taken, all appropriate action, and to do, or cause to be done, all things necessary, proper or advisable under applicable laws to consummate and make effective any such transfer of the Brazil Business to Total, including, without limitation, using reasonable best efforts to obtain all licenses, permits, consents, approvals, authorizations, qualifications and orders of the competent governmental entities. Without limiting the generality of the foregoing, the parties shall, when required in order to effect such transfer of the Brazil Business to Total, make all necessary filings, and thereafter make any other required or appropriate submissions, under any Competition Law and shall supply as promptly as practicable to the appropriate governmental entity any additional information and documentary material that may be requested pursuant to any Competition Law.
(iv)    The “Brazil Business Fair Market Value” shall mean the amount, determined as of the date that Total acquires all of the common and preferred equity interests in JVCO, equal to the fair market value that a willing buyer would pay a willing seller in an arms’-length transaction to acquire the Brazil Business, assuming that the Brazil Business was being sold in a manner designed to maximize bids, when neither the buyer nor the seller was acting under compulsion and when both have reasonable knowledge of the relevant facts, as determined by the relevant Advisor in accordance with Section 4.2(c).
(v)    Amyris and Total shall negotiate in good faith for a period of 20 days from the date of the notice from Total to Amyris of its intention to acquire the Brazil Business to try to determine the Brazil Business Fair Market Value. If Amyris and Total are unable to reach a mutual determination of the Brazil Business Fair Market Value within such 20-day period, then each of Amyris and Total shall promptly engage (at its own expense) a qualified, recognized appraiser of international standing (such as, by way of example only, the valuation group of an international accounting firm or a global 

A-2

investment bank) with substantial experience in valuing companies with a size, organization, and assets similar to that of the Brazil Business (each, an “Advisor”), and each such Advisor shall deliver a written opinion as to its determination of the Brazil Business Fair Market Value (each, an “Advisor’s Report”) to each of Amyris and Total concurrently within 20 Business Days of its engagement (the “Opinion Period”). If the Brazil Business Fair Market Value determined by an Advisor is presented in such Advisor’s Report as a range of values, then the Brazil Business Fair Market Value for purposes of such Advisor’s Report shall be deemed to be the arithmetic average of such range. If only one Advisor timely delivers its Advisor’s Report, the value determined by such Advisor shall be deemed to be the Brazil Business Fair Market Value for purposes hereof. If both of the Advisors timely deliver an Advisor’s Report and if the difference between the values submitted by each Advisor equals 10% or less of the higher value, then the Brazil Business Fair Market Value for purposes hereof shall be deemed to be the arithmetic average of the values submitted by such Advisors. If the difference between the two values is greater than 10% of the higher value, then Amyris and Total shall negotiate in good faith for a period of five Business Days from the expiration of the Opinion Period to try to determine the Brazil Business Fair Market Value. If, during such period, Amyris and Total cannot agree on the Brazil Business Fair Market Value, then they shall jointly select a third Advisor that has not been engaged by either Amyris or any of its Affiliates or Total or any of its Affiliates (but only with respect to matters involving the New Energies business of Total’s ultimate parent holding company and any other entity then operating what is currently the New Energies business) in any capacity during the six months preceding such date, which third Advisor may, but shall not be required to be, an Approved Valuation Firm. Such third Advisor shall be required to choose only one of the two previously-submitted values as the Brazil Business Fair Market Value and shall not be authorized to determine a new, third value. If Amyris and Total cannot agree on the third Advisor, then their respective Advisors shall together be instructed to select as the third Advisor an Advisor that has not been engaged by either Amyris or any of its Affiliates or Total or any of its Affiliates (but only with respect to matters involving the New Energies business of Total’s ultimate parent holding company and any other entity then operating what is currently the New Energies business) in any capacity during the six month period preceding such date, which third Advisor may, but shall not be required to be, an Approved Valuation Firm. Neither Amyris nor Total (or any Affiliate or representative of either Amyris or Total) shall communicate unilaterally with the third Advisor. The third Advisor will be instructed to deliver to Amyris and Total concurrently, within 15 Business Days of its engagement, an Advisor’s Report selecting which of the two values submitted by the original two Advisors better approximates the Brazil Business Fair Market Value. The value chosen by the third Advisor shall then be deemed to be the Brazil Business Fair Market Value and will be non-appealable, final and binding on the parties for purposes hereof. Amyris and Total covenant to provide the Advisors with complete and accurate information to allow the Advisors to accurately and independently estimate the Brazil Business Fair Market Value. The Advisors shall, in determining the Brazil Business Fair Market Value, consider all material information resulting from such diligence and access, subject to the definition of “Brazil Business Fair Market Value” set forth herein. Each of Amyris and Total shall bear the fees and expenses of its Advisor, and they shall split equally the fees and expenses of the third Advisor. Each party shall use its respective 

A-3

reasonable efforts to assist in the determination of the Brazil Business Fair Market Value, including providing any information reasonably required for such purpose.
1.3    Contribution of Brazil Business to JVCO Following Final Go Decision Date.
(vi)    If promptly following the Final Go Decision Date Amyris shall own 50% of the capital stock of JVCO, then if Total delivers written notice to Amyris within 90 days following the Final Go Decision Date that JVCO shall acquire the Brazil Business, the parties shall determine the Ground Floor Price pursuant to Section 4.3(b). If promptly following the Final Go Decision Date Amyris shall own less than 50% of the capital stock of JVCO, then if Total delivers written notice to Amyris within 90 days following the Final Go Decision Date that JVCO shall acquire the Brazil Business, the parties shall negotiate in good faith to agree on a fair sale price for the Brazil Business (the “Brazil Business Sale Price”). Within 60 days following determination of the Ground Floor Price or the Brazil Business Sale Price, as applicable, (i) Total shall transfer to JVCO an amount of readily available cash equal to its pro rata share (based on its pro rata ownership of JVCO) of the Ground Floor Price or the Brazil Business Sale Price, as applicable (which transfer shall not be a capital contribution or a shareholder loan and shall not change the pro rata ownership of JVCO); and (ii) Amyris will contribute the Brazil Business to JVCO in exchange for the payment by JVCO to Amyris of the Ground Floor Price or the Brazil Business Sale Price, as applicable, which contribution shall be effected by such documents as, in the mutual agreement of Total (on behalf of JVCO) and Amyris, are necessary or appropriate to convey the Brazil Business; provided, that Amyris shall be required to provide customary representations or warranties agreed to by the parties for this kind of transactions including basic representations and warranties regarding its authority to enter into the sale documentation, the due execution and binding nature of the sale documentation by Amyris, and that its participation in the sale will not contravene, or require a consent, waiver or approval pursuant to, any applicable law or pursuant to any agreement to which it is subject. If the Brazil Business is to be transferred to JVCO pursuant to the prior sentence, each of the parties shall use its reasonable best efforts to take, or cause to be taken, all appropriate action, and to do, or cause to be done, all things necessary, proper or advisable under applicable laws to consummate and make effective any such transfer of the Brazil Business to JVCO, including, without limitation, using reasonable best efforts to obtain all licenses, permits, consents, approvals, authorizations, qualifications and orders of the competent governmental entities. Without limiting the generality of the foregoing, the parties shall, when required in order to effect such transfer of the Brazil Business to JVCO, make all necessary filings, and thereafter make any other required or appropriate submissions, under any Competition Law and shall supply as promptly as practicable to the appropriate governmental entity any additional information and documentary material that may be requested pursuant to any Competition Law.
(vii)    The “Ground Floor Price” means Amyris’ investment into the Brazil Business from November 2011 through the date such business is contributed to JVCO, including, but not limited to, technical development activities undertaken in Brazil, industrial and supply chain, capital expenditures, working capital, sales and marketing commitments, negative operating cash flow (i.e., not discounted by any losses) net of any liabilities of the Brazil Business which are assumed by JVCO and net of any subsidies 

A-4

provided to the Brazil Business, which are not subject to any repayment or claw-back obligation retained by Amyris, which amount shall be mutually agreed to between Amyris and Total; provided, however, that if Amyris and Total are unable to agree upon such Ground Floor Price within 60 days of Total’s election to cause the Brazil Business to be acquired by JVCO, then either Amyris or Total may submit all matters that remain in dispute with respect to the determination of the Ground Floor Price to a mutually agreed independent “Big Four” accounting firm or an Advisor (such accounting firm or Advisor, the “Independent Accounting Firm”). Within 60 days after such firm’s selection, the Independent Accounting Firm shall make a final determination, binding on the parties hereto, of the appropriate amount of each disputed item submitted to the Independent Accounting Firm. With respect to each disputed item, such determination, if not in accordance with the position of either party, shall not be in excess of the higher, nor less than the lower, of the amounts advocated by the parties with respect to such disputed item. The cost of the Independent Accounting Firm’s review and determination shall be borne in the same proportion as the aggregate amount of the disputed items that is unsuccessfully disputed by each (as determined by the Independent Accounting Firm) bears to the total amount of disputed items submitted to the Independent Accounting Firm. During the review by the Independent Accounting Firm, Amyris and its accountants will make available to the Independent Accounting Firm such information, books and records and work papers, as may be reasonably required by the Independent Accounting Firm to fulfill its obligations under this Section 4.3(b); provided, however, that the external auditors of Amyris shall not be obligated to make any work papers available to the Independent Accounting Firm except in accordance with such auditors’ normal disclosure procedures and then only after such Independent Accounting Firm has signed a customary agreement relating to such access to work papers in form and substance reasonably acceptable to such auditors.
(viii)    In the event that Total makes the Jet Go Decision, Amyris shall have no obligation to contribute any of the assets of the Brazil Business related to the development, production and commercialization of Farnesane Diesel Products, and Amyris shall have no obligation to contribute any of the assets of the Brazil Business related to the development, production and commercialization of Farnesane Jet Products unless Amyris and Total shall have concluded that it is reasonably feasible to restructure the Brazil Business to separate the assets of the Brazil Business related to the development, production and commercialization of Farnesane Diesel Products from the assets of the Brazil Business related to the development, production and commercialization of Farnesane Jet Products, in which event Total and Amyris shall seek to cause to be contributed to JVCO pursuant to this Section 4.3 only the assets of the Brazil Business related to the development, production and commercialization of Farnesane Jet Products.
1.4    Sale of Brazil Business to Total on Deadlock. If Total shall acquire all of the common and preferred equity interests of Amyris in JVCO pursuant to Section 7.02(d) of the Shareholders’ Agreement, then if Total delivers written notice to Amyris within 90 days following such acquisition of common and preferred equity interests of Amyris in JVCO that Total intends to acquire the Brazil Business, the parties shall negotiate in good faith to agree on the Brazil Business Sale Price. Within 60 days following determination of the Brazil Business Sale Price, Amyris will sell the Brazil Business to Total in exchange for the 

A-5

payment by Total to Amyris of the Brazil Business Sale Price, which sale shall be effected by such documents as, in the mutual agreement of Total and Amyris, are necessary or appropriate to convey the Brazil Business. If the Brazil Business is to be sold to Total pursuant to the prior sentence, each of the parties shall use its reasonable best efforts to take, or cause to be taken, all appropriate action, and to do, or cause to be done, all things necessary, proper or advisable under applicable laws to consummate and make effective any such transfer of the Brazil Business to Total, including, without limitation, using reasonable best efforts to obtain all licenses, permits, consents, approvals, authorizations, qualifications and orders of the competent governmental entities. Without limiting the generality of the foregoing, the parties shall, when required in order to effect such transfer of the Brazil Business to Total, make all necessary filings, and thereafter make any other required or appropriate submissions, under any Competition Law and shall supply as promptly as practicable to the appropriate governmental entity any additional information and documentary material that may be requested pursuant to any Competition Law. Customary representations and warranties for an acquisition of this type will be provided by Amyris.

A-6

Exhibit B
Commercial Technology Transfer Package

A commercial technology transfer package should include the following:

1.Strain information:
a.Back-ground strain design information such as strain information, genetic background, sequence information, genetic modifications information.  e.g., 
I.Strain ancestor and lineage of the current strain including each of the rational or directed strain engineering changes, what type of changes – deletion, insertion, ploidy changes, description of the changes, locus at which the changes were engineered and what were the resulting genii of the modified strain at each step.

b.Strain storage and propagation 
I.SOP for the overall strain storage including detailed media recipes for preserving strain 
II.SOP for strain revival including steps all the way from seed vial to inoculums tanks for the propagation media for revival of the strain 

c.Feed-stock information – ingredient information, sourcing, specificities, testing
I.Feed-stock sources and details of handling the feedstock 

2.Details of a fermentation run at all scales (including from inoculum to shake-flask to 300L to 1m3, 40 m3 and 200 m3 production reactors):
a.    SOP’s for media, sterilization, fill and draw 
b.    Sampling intervals, sampling protocols
c.    Performance and specific testing at each step, protocols for tests at each stage 
d.    Historical data of runs at  all scales (including 1m3, 40 m3 and 200 m3) to register and monitor variability
  
3.Process design (including Brotas data):
a.    Detailed manufacturing process, process narrative, operating conditions 
b.    PFD’s design basis, heat/material balance, with identified streams
c.    Equipment list and material of construction – vessel specifications, identify an special modifications, performance required, design and fabrication codes, vendor and model numbers
d.    Utility flow and diagrams – all major inputs, outputs, stream compositions, flow rates
e.    Waste-water specification
f.    Routine maintenance, testing, replacements 

B-1

4.Process book including process control and details of the operation:
a.    Aseptic design and operation,  sterilization and cleaning (SIP/CIP) procedures and schedules 
b.    batch and fed-batch operational details, 
c.    feeding algorithm details, 
d.    process control and monitoring strategies
e.    historic data of all prior runs with the strains – access to database of prior runs

And any other information that is necessary for being able to operate the strain in commercial settings.

B-2

Exhibit C
Initial Package

Current process book for the current strain Amyris is using for the commercial production of farnesene and the following with respect to the all of the designated Intermediate Strains:
1.Strain information:
a.Back-ground strain design information such as strain information, genetic background, sequence information, genetic modifications information.  e.g., 
I.Strain ancestor and lineage of the current strain including each of the rational or directed strain engineering changes, what type of changes – deletion, insertion, ploidy changes, description of the changes, locus at which the changes were engineered and what were the resulting genii of the modified strain at each step.

b.Strain storage and propagation 
i.SOP for the overall strain storage including detailed media recipes for preserving strain 
ii.SOP for strain revival including steps all the way from seed vial to inoculums tanks for the propagation media for revival of the strain

c.Feed-stock information – ingredient information, sourcing, specificities, testing
II.Feed-stock sources and details of handling the feedstock 
III.Testing results for content of sugar or other impacting ingredients
IV.Seasonal variation information or data 
V.Protocols for any adjustment made to feedstock

2.Current best details of a fermentation run at all scales (including from inoculum to shake-flask to 300L to 1m3, 40 m3 and 200 m3 production reactors - if not at the largest scale then information on best scale at which this strain is current been running):
a.    SOP’s for media, sterilization, fill and draw 
b.    Sampling intervals, sampling protocols
c.    Performance and specific testing at each step, protocols for tests at each stage 
d.    Historical data of runs at all scales (including 1m3, 40 m3 and 200 m3) to register and monitor variability
3.Current best process design (including Brotas data):
a.Detailed manufacturing process, process narrative, operating conditions 
b.PFD’s design basis, heat/material balance, with identified streams
c.Equipment list and material of construction – vessel specifications, identify an special modifications, performance required, design and fabrication codes, vendor and model numbers
d.Utility flow and diagrams – all major inputs, outputs, stream compositions, flow rates
e.Waste-water specification
f.Routine maintenance, testing, replacements 

B-3

4.Current best process book including process control and details of the operation:
a.Aseptic design and operation, design constraints,  sterilization and cleaning (SIP/CIP) procedures and schedules 
b.batch and fed-batch operational details, 
c.feeding algorithm details, 
d.process control and monitoring strategies
e.Performance data of recent runs 
Any other information that is necessary for being able to operate the strain in commercial settings.

C-1

Exhibit D
Section 6.1 of Collaboration Agreement
Subject to Section 11 of the Second Amendment, Section 6.1 is as follows as of the Effective Date:
6.1    Ownership.  
(a)    Background IP.  Subject to the license grants set forth in this Agreement, (i) TOTAL shall retain all of its right, title and interest in and to the TOTAL Background IP, and (ii) AMYRIS shall retain all of its right, title and interest in and to the AMYRIS Background IP.  Notwithstanding any other provision of this Agreement, TOTAL Background IP shall not be deemed to be introduced as TOTAL Included IP in any aspect of R&D Activities, Improvement Scope Activities, or Commercialization activities without an express election by TOTAL and by following the process set forth in Section 6.1(c)(i) below.  
(b)    Non-Collaboration IP.  Subject to the license grants set forth in this Agreement with respect to Included IP, (i) TOTAL shall retain all of its right, title and interest in and to the TOTAL Non-Collaboration IP, and (ii) AMYRIS shall retain all of its right, title and interest in and to the AMYRIS Non-Collaboration IP.  Notwithstanding any other provision of this Agreement, TOTAL Non-Collaboration IP shall not be deemed to be introduced as TOTAL Included IP in any aspect of R&D Activities, Improvement Scope Activities, or commercialization activities without an express election by TOTAL and by following the process set forth in Section 6.1(c)(i) below. Notwithstanding any other provision of this Agreement, AMYRIS Non-Collaboration IP shall not be deemed to be introduced as AMYRIS Included IP in any aspect of R&D Activities, Improvement Scope Activities, or commercialization activities without an express election by AMYRIS and by following the process set forth in Section 6.1(c)(i) below, other than AMYRIS Non-Collaboration IP which is automatically deemed to be AMYRIS Included IP as set forth in Section 6.1(c)(ii).
(c)    Included IP. 
(i)    From time to time during the Term of this Agreement, a Party may choose, in its sole discretion, to introduce its Non-Collaboration IP and/or its Background IP into the R&D Collaboration to facilitate the performance of the R&D Activities, the activities of a JV Company related to a Product or under the Improvement Scope Activities.  In each such case, such Party shall provide advance written notice to the Joint Steering Committee identifying the nature of such Non-Collaboration IP and/or such Background IP and a proposal for how such Non-Collaboration IP and/or Background IP, as applicable, may be used in the R&D Collaboration, the activities of a JV Company related to a JV Product or the Improvement Scope Activities.  If the Joint Steering Committee agrees to accept the terms under which the Non-Collaboration IP and/or Background IP, as applicable, may be used in the R&D Collaboration or the activities of a JV Company related to a JV Product or the Improvement Scope Activities, such Non-Collaboration IP and/or Background IP, as applicable, shall become Included IP.  In any event, each Party agrees not to assert 

D-1

infringement of any intellectual property it Controls by the other Party or any of its Affiliates for asserting its rights, or performing its obligations, under the Agreement or the documents establishing the JV Company. 
(ii)    Notwithstanding the following, any AMYRIS Background IP and AMYRIS Non-Collaboration IP, in each case, encompassing general means of practicing synthetic biology, including without limitation, methods and means to construct and test a Strain (including without limitation all related software, workflow, apparatus or arrangement of apparatuses, knowledge database systems, processes, systems and technology for the design, selection, engineering and development of Strains) shall be deemed AMYRIS Included IP without further action on the part of AMYRIS or the Joint Steering Committee, and such AMYRIS Included IP may be utilized by the Parties for the performance of the R&D Activities, the activities of a JV Company related to a Product or the Improvement Scope Activities, according to the terms of the Agreement.  However, TOTAL may veto the inclusion of selected AMYRIS Non-Collaboration IP that would otherwise constitute Included IP, but such veto must be exercised in connection with the voting of its representatives on the Joint Steering Committee.
(iii)    From time to time during the Term of this Agreement, Inventions Controlled by a Third Party may be used in the performance of the R&D Activities, the activities of a JV Company related to a Product and the Improvement Scope Activities. Terms and provisions relating to such Third Party Inventions shall be agreed on in writing by the Parties on a case by case basis.
(d)    Collaboration IP.
(i)    AMYRIS-Owned Collaboration IP.  As between the Parties, subject to the license grants set forth in this Agreement, AMYRIS shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to the AMYRIS Tools IP and MEV Pathway IP conceived and reduced to practice in the performance the R&D Activities and/or the performance of activities on behalf of the JV Company related to a Product or the means of making the Product (“AMYRIS Owned Collaboration IP”).  TOTAL hereby assigns to AMYRIS, without further consideration, all right, title and interest that TOTAL may have from time to time (other than by virtue of the license grants in this Article 6) in any AMYRIS Tools IP and MEV Pathway IP and shall, at AMYRIS’ reasonable expense, execute all documents and take all actions reasonably requested by AMYRIS from time to time to perfect AMYRIS’ title to and ownership thereof.  
(ii)    Jointly-Owned Collaboration IP.  As between the Parties, subject to the license grants set forth in this Agreement, AMYRIS and TOTAL shall have joint ownership of all right, title and interest on a worldwide basis in and to the New Tools IP and Main IP conceived and reduced to practice in the performance of the R&D Activities and/or the performance of activities on behalf of the JV Company related to a Product or the means of making the Product, other than TOTAL Owned Collaboration IP (“Jointly Owned Collaboration IP”).  Each Party shall have the right to use and exploit all Jointly-Owned Collaboration IP without duty to account to the other joint owner and without obligation to obtain consent of the other joint owner, except as may otherwise be provided in the 

D-2

Agreement or in the documents establishing the JV Company.  Notwithstanding the foregoing, a license under each Party’s respective Background IP and Non-Collaboration IP, if required for the other Party’s use and exploitation of Jointly-Owned Collaboration IP, is not granted herein unless otherwise expressly provided in this Article 6. Each Party shall have an undivided one half ownership interest in such Jointly-Owned Collaboration IP and each Party hereby assigns to the other Party, without further consideration, such right, title and interest that it may have from time to time (other than by virtue of the license grants in this Article 6) in any and all Jointly-Owned Collaboration IP as required to effect such co-ownership.
(iii)    TOTAL-Owned Collaboration IP.  As between the Parties, subject to the license grants set forth in this Agreement, TOTAL shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to Main IP and New Tools IP conceived and reduced to practice in the performance of R&D Activities under a New Technology Project conducted under the TOTAL R&D Option (the "TOTAL-Owned Collaboration IP"). AMYRIS hereby assigns to TOTAL, without further consideration, all right, title and interest that AMYRIS may have from time to time (other than by virtue of the license grants in this Article 6) in any such IP and shall, at TOTAL’s reasonable expense, execute all documents and take all actions reasonably requested by TOTAL from time to time to perfect TOTAL’s title to and ownership thereof.
(iv)    Each Party shall have the right, on reasonable notice, to inspect and review the specific records maintained by the other Party reflecting the Collaboration IP made by such other Party, solely to the extent reasonably needed by the reviewing Party for exercising its rights or performing its obligations under this Agreement.
(e)    Improvement Scope IP.  Improvement Scope IP will be (a) jointly owned by TOTAL and AMYRIS, if the Improvement Right of First Refusal has been accepted by the corresponding Party (in a manner analogous to the Jointly-Owned Collaboration IP as described in Section 6.1.(d)(ii)) (the "Jointly Owned Improvement Scope IP"), or (b) owned solely by the Improving Party (TOTAL , for the “TOTAL Owned Improvement Scope IP” or AMYRIS for the “AMYRIS Owned Improvement Scope IP”) if the Improvement Right of First Refusal has been rejected by the other Party.

D-3

Exhibit E
List of the Member States of the European Union

The following States are members of the European Union as of the Effective Date:
1.Austria 
2.Belgium  
3.Bulgaria 
4.Croatia 
5.Cyprus 
6.Czech Republic
7.Denmark 
8.Estonia 
9.Finland 
10.France 
11.Germany  
12.Greece  
13.Hungary  
14.Ireland 
15.Italy 
16.Latvia 
17.Lithuania
18.Luxembourg 
19.Malta 
20.Netherlands 
21.Poland 
22.Portugal
23.Romania 
24.Slovakia 
25.Slovenia 
26.Spain 
27.Sweden 
28.United Kingdom

E-1

Exhibit F
Known By-Products

		
	1.
	Identified as of the Effective Date:  The following compositions: (i) dead yeast cells, (ii) ethanol, (iii) farnesol, (iv) farnesene dimer, (v) triglyceride, (vi) hexahydrofarnesol, (vii) hydrogenated farnesene dimer, or (viii) combination of items in (i) through (vii) with or without farnesene and/or farnesane.  

		
	2.
	Identified after the Effective Date:

F-1Amyris 2013 10-K Ex 10.25 PledgeofJVCOSharesbyAmyris12-02-13FINAL

	
					
	CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

PLEDGE OF SHARES:

Total Amyris BioSolutions B.V.

having its official seat in Amsterdam, the Netherlands.

Deed dated 2 December 2013

Contents:

-    certified copy of the deed of pledge of shares in the capital of Total Amyris BioSolutions
B.V.

by:    Amyris, Inc.

to:    Total Energies Nouvelles Activites USA

executed on 2 December 2013 before B.J. Kuck, civil law notary in Amsterdam, the Netherlands.

1

BJK/PS/L-201990

DEED OF PLEDGE OF SHARES
(Total Amyris BioSolutions B.V.)
This second day of December two thousand thirteen, there appeared before me, [*], civil law notary in Amsterdam, the Netherlands:     
[*], with office address at [*], born in [*],     
in this respect acting as attorney-in-fact of:     
		
	(1)
	Amyris, Inc., a corporation incorporated under the laws of the State of Delaware, United States of America, having its office at 5885 Hollis Street, Suite 100, Emeryville, CA 94608, United States of America, registered with the Secretary of State of Delaware, United States of America, under number 4768633 (the “Grantor”);     

		
	(2)
	Total Energies Nouvelles Activités USA, a company incorporated under the laws of France (société par actions simplifiée), having its official seat (siège social) at 24 Cours Michelet, 92800 Puteaux, France, registered with the French Commercial Register (Registre du Commerce et des Sociétés, Greffe du Tribunal de Commerce de Nanterre) under number 505 028 118 (the “Secured Party”); and     

		
	(3)
	Total Amyris BioSolutions B.V., a private company with limited liability incorporated under the laws of the Netherlands (besloten vennootschap met beperkte aansprakelijkheid), having its official seat (statutaire zetel) in Amsterdam, the Netherlands, and its office at Claude Debussylaan 24, 1082 MD Amsterdam, the Netherlands, registered with the Dutch Trade Register of the Chambers of Commerce under number 59337494 (the “Company”),     

(the Grantor and the Secured Party jointly the “Parties” and each a “Party”).     
The aforementioned proxies appear from three written powers of attorney, copies of which have been attached to this deed (Annexes).     
The person appearing declared the following:     

[*] Certain portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

A17046371                                           Linklaters LLP

2

Preliminary statements:     
		
	(A)
	The Grantor owns (a) the voting share A (the “Class A Share”) of the Company and (b) all of the preference shares (the “Preferred Shares”) of the Company, which preference shares do not have voting rights in the general meeting of the Company. The Class A Share has been acquired by the Grantor, by participation in the capital of the Company at incorporation, pursuant to a deed executed before B.J. Kuck, civil law notary (the “Notary”), in Amsterdam, the Netherlands, on the twenty-ninth day of November two thousand thirteen, and the Preferred Shares have been acquired by the Grantor, by participation in the capital of the Company after incorporation, pursuant to a deed executed before the Notary in Amsterdam, the Netherlands, on the second day of December two thousand thirteen.     

		
	(B)
	The Grantor is indebted to the Secured Party pursuant to the Securities Purchase Agreement dated on the thirtieth day of July two thousand twelve (the “Purchase Agreement”), between the Grantor and the Secured Party under which the Grantor has issued and may issue on the dates specified therein convertible promissory notes (collectively, the “Convertible Notes” and each, a “Convertible Note”) to the Secured Party. Pursuant to the terms of the Purchase Agreement, the Secured Party may extend additional credit to the Grantor. The Grantor’s obligations under the Purchase Agreement are secured by the Grantor’s intellectual property and related assets pursuant to the “Intellectual Property Security Agreement” dated on the twenty-sixth day of April two thousand thirteen (the “Security Agreement”), made by the Grantor in favor of the Secured Party. The Secured Party has agreed to release its lien under the Security Agreement when the Secured Party and the Grantor have entered into final documentation regarding the establishment of the Company, which includes this deed and the rights granted hereunder, and such documentation has become effective.     

		
	(C)
	The Grantor is further indebted to the Secured Party pursuant to the Class A Secured Promissory Note dated as of the date hereof (the “Class A Note”), made by the Grantor in favor of the Secured Party in the original principal amount of fifty thousand euro (EUR 50,000), the proceeds of which were used by the Grantor to acquire the Class A Share.

		
	(D)
	The Grantor has granted an option (the “Purchase Option”) to the Secured Party to purchase all of the Grantor’s rights, title and interests in and to the Class A Share and the Preferred Shares pursuant to the articles of association of the Company (the “Articles of Association”). The Secured Party has a right of first offer (the “Right of First Offer”) to purchase the Class A Share and the Preferred Shares in certain circumstances pursuant to the Articles of Association.

		
	(E)
	To facilitate the exercise of the Purchase Option, the Grantor will transfer the Class A Share and the Preferred Shares, subject to the Lien granted pursuant to this deed, by a deed (the “Transfer Deed”) to be executed on the date hereof before the Notary to Stichting Total Amyris BioSolutions, a foundation incorporated under the laws of the Netherlands (stichting), having its official seat (statutaire zetel) in Amsterdam, the Netherlands, and its office at Claude

A17046371                                           Linklaters LLP

3

Debussylaan 24, 1082 MD Amsterdam, the Netherlands, registered with the Dutch Trade Register of the Chambers of Commerce under number 59329483, as escrow agent (in such capacity, the “Escrow Agent”) pursuant and subject to the Escrow Agreement dated as of the date hereof (the “Escrow Agreement”), among the Grantor, the Secured Party and the Escrow Agent.     
		
	(F)
	To secure its obligations under the Purchase Option and the Right of First Offer, obtain the proceeds of the Class A Note, consummate the establishment of the Company, obtain the release of the collateral under the Security Agreement and obtain future additional credit under the Purchase Agreement, the Grantor desires to grant to the Secured Party a security interest in and lien on all of its rights, title and interests in and to the Class A Share and the Preferred Shares and other Collateral (as defined hereinafter) to secure the Secured Obligations (as defined hereinafter) pursuant to the terms of this deed.     

Agreement:     
In consideration of the foregoing and the mutual agreements contained in this deed, the receipt and sufficiency of which are acknowledged, the Parties hereby agree as follows:     
		
	1
	Interpretation     

This deed is to be interpreted in accordance with the rules of construction set forth below. Capitalized terms used in this deed and not otherwise defined have the meanings set forth for such terms in article 1.1. All annexes, schedules and exhibits to this deed are deemed to be a part of this deed.     
		
	1.1
	Definitions     

Terms defined in the UCC that are not otherwise defined in this deed are used herein as defined in the UCC. As used in this deed, the plural includes the singular and the singular includes the plural. As used in this deed, the following terms have the following meanings:     
“Articles of Association” has the meaning set forth for such term in the preliminary statements.     
“Class A Note” has the meaning set forth for such term in the preliminary statements.     
“Class A Share” has the meaning set forth for such term in the preliminary statements.     
“Collateral” has the meaning set forth for such term in article 2.1.     
“Convertible Note” and “Convertible Note” ” has the meaning set forth for such term in the preliminary statements.     
“Dividends” means (a) dividends and distributions of any kind and any other sum received or receivable in respect of that Pledged Interest, (b) rights, shares, money or other assets accruing or offered by way of redemption, bonus, option or otherwise in respect of that Pledged Interest, (c) allotments, offers and rights accruing or offered in respect of that Pledged Interest and (d) other rights and assets attaching to, deriving from or exercisable by virtue of the ownership of, that Pledged Interest, other than voting rights.     
“Equity Interests” means shares of capital stock, partnership interests, membership interests in a limited liability company, beneficial interests in a trust or other equity

A17046371                                           Linklaters LLP

4

ownership interests in a Person, and any warrants, options or other rights entitling the holder thereof to purchase or acquire any such equity interest.     
“Escrow Agent” has the meaning set forth for such term in the preliminary statements.     
“Escrow Agreement” has the meaning set forth for such term in the preliminary statements.     
“Event of Default” means either or both (i) any event or circumstance constituting an Event of Default under, and as defined in, the Convertible Notes, or (ii) following the occurrence of an Event of Default under, and as defined in, the Convertible Notes, the Grantor fails or neglects to perform, keep or observe any of its covenants in any manner that impairs, limits restricts, prevents, or otherwise adversely affects Lender’s, as defined in the Convertible Notes, ability to exercise its Purchase Option or Right of First Offer rights, both as defined in the Articles of Association, under article 9 of the Articles of Association, or its purchase rights under an Amyris Change of Control under, and as defined in, section 8.03 of the Shareholders Agreement.     
“Indemnitee” has the meaning set forth for such term in article 2.11.     
“Insolvency Proceeding” means any Event of Default described in article 5(vii) or 5(viii) of the Convertible Notes.     
“Lien” means any security interest, pledge, mortgage, encumbrance, lien, charge, adverse claim of ownership or use, or other encumbrance of any kind (including any agreement to give any of the foregoing, any conditional sale or other title retention agreement or any lease in the nature thereof). For the avoidance of doubt, “Lien” shall not include any transfer restrictions imposed under securities laws, or any options, transfer restrictions or purpose limitations pursuant to the Transaction Documents or the Organizational Documents.     
“Notary” has the meaning set forth for such term in the preliminary statements.     
“Organizational Documents” has the meaning set forth for such term in article 2.1(c).     
“Parent” has the meaning set forth for such term in the definition of the term “subsidiary”.     
“Person” means any individual, corporation (including any non-profit corporation), limited liability company, joint stock company, general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, firm, governmental entity or other enterprise, association, organization or entity.     
“Pledged Interests” has the meaning set forth for such term in article 2.1(a).     
“Preferred Shares” has the meaning set forth for such term in the preliminary statements.     
“Preferred Shares Option Price” has the meaning set forth for such term in the Articles of Association.     
“Purchase Agreement” has the meaning set forth for such term in the preliminary statements.     
“Purchase Option” has the meaning set forth for such term in the preliminary statements.     
“Right of First Offer” has the meaning set forth for such term in the preliminary statements.     
“Secured Obligations” means:     

A17046371                                           Linklaters LLP

5

		
	(a)
	all amounts, direct or indirect, contingent or absolute, of every type or description, and at any time existing, owing by the Grantor to the Secured Party pursuant to the terms of the Purchase Agreement or the Convertible Notes;     

		
	(b)
	all losses or damages, direct or indirect, contingent or absolute, of every type or description, and at any time existing, including liquidated damages, suffered by the Secured Party as a result of the Grantor’s breach of any of its obligations with respect to the Purchase Option or the Right of First Offer;      

		
	(c)
	all amounts, direct or indirect, contingent or absolute, of every type or description, and at any time existing, owing by the Grantor to the Secured Party pursuant to the terms of the Class A Note; and     

		
	(d)
	any amounts owing by the Grantor to the Secured Party under the indemnification provisions of the Escrow Agreement.     

in each case including any amounts incurred or arising during the pendency of any bankruptcy, insolvency, reorganization, receivership or similar proceeding, regardless of whether allowed or allowable in such proceeding or subject to an automatic stay under section 362(a) of the United States Bankruptcy Code.     
“Security Agreement” has the meaning set forth for such term in the preliminary statements.     
“Shareholders Agreement” means the “Shareholders’ Agreement” dated as of the date hereof, by and among the Grantor, the Secured Party and the Company.     
“Subsidiary” of any Person (the “parent”) means and includes any other Person in which the parent directly or indirectly through one or more Persons holds more than fifty per cent. (50%) of the Equity Interests of such other Person. Unless otherwise expressly provided, all references to “Subsidiary” herein mean a Subsidiary of the Grantor.     
“Termination Date” means the earlier of (a) the first date that (i) the Secured Obligations (other than indemnification obligations) have been indefeasibly repaid in full or are otherwise cancelled and extinguished pursuant to, as applicable, the Convertible Notes, the Class A Note and the Organizational Documents, (ii) the Secured Party has no further commitment to provide financing to the Grantor under the Purchase Agreement, and (iii) the Purchase Option and the Right of First Offer have expired, been exercised or terminated and (b) the date the Final Shareholders’ Agreement (as defined in the Shareholders Agreement) is executed and delivered.     
“Transaction Documents” means this deed, the Purchase Agreement, the Convertible Notes, the Class A Note, the Shareholders Agreement and all other agreements, instruments, certificates or other documents now or hereafter executed or delivered to, or in favor of, the Secured Party in connection therewith or the transactions contemplated thereby.     
“Transfer Deed” has the meaning set forth for such term in the preliminary statements.     
“UCC” means the Uniform Commercial Code of the State of New York or of any other jurisdiction the laws of which are required as a result thereof to be applied in connection with the attachment, perfection or priority of, or remedies with respect to, the Secured Party’s security interest in any Collateral.     

A17046371                                           Linklaters LLP

6

“Valuation Advisor” has the meaning set forth for such term in the Articles of Association.     
		
	1.2
	Use of certain terms     

As used in this deed, “include,” “includes” and “including” have the inclusive meaning of “including without limitation.” All pronouns and any variations thereof refer to masculine, feminine, neuter, singular or plural as the identity of the Person or Persons may require.     
		
	1.3
	Headings and references     

Article and other headings are for reference only, and do not affect the interpretation or meaning of any provision of this deed. Unless otherwise provided, references to articles, sections, clauses, annexes, schedules and exhibits refer to articles, sections, clauses, annexes, schedules and exhibits of this deed. The words “hereof,” “herein,” “hereby,” “hereunder” and other similar terms of this deed refer to this deed as a whole and not exclusively to any particular provision of this deed. Unless otherwise expressly indicated in this deed, the words “above” and “below,” when following a reference to a clause of any agreement, instrument or other document, refer to a clause within the same article of such agreement, instrument or document. References in this deed to this deed, any other agreement, instrument or document are deemed to (a) refer to this deed, such other agreement, instrument or document, as the case may be, as the same may be amended, restated, supplemented or otherwise modified from time to time under the provisions hereof or thereof, unless expressly stated otherwise or unless such amendment, restatement, supplement or modification is not permitted by the terms of this deed and (b) include all schedules, exhibits and appendices thereto. References in this deed to any law, rule, statute or regulation are deemed to refer to such law, rule, statute or regulation as it may be amended, supplemented or otherwise modified from time to time, and any successor law, rule, statute or regulation, in each case as in effect at the time any such reference is operative. Any reference to a Person includes the successors, assigns, participants and transferees of such Person, but such reference will not increase, decrease or otherwise modify in any way the provisions in this deed or any other agreement, instrument or document governing the assignment of rights and obligations under or the binding effect of any provision of this deed or any other agreement, instrument or document.     
		
	2
	Security interest     

		
	2.1
	Grant of security interest     

As security for the prompt and complete payment when due of all of the Secured Obligations, the Grantor hereby grants to the Secured Party a security interest in all of its right, title and interest in, to and under all of the following property, whether now existing or hereafter from time to time acquired and wherever located (collectively, the “Collateral”):     
		
	(a)
	all investment property and general intangibles consisting of the Class A Share, the Preferred Shares and any other ownership, equity or other similar interests in the capital of the Company (collectively, the “Pledged Interests”);     

		
	(b)
	all certificates, instruments, writings and securities evidencing the Pledged Interests;     

A17046371                                           Linklaters LLP

7

		
	(c)
	all options or other rights to acquire any Pledged Interests under the Articles of Association and the Shareholders Agreement (collectively, the “Organizational Documents”);     

		
	(d)
	all Dividends and other property or proceeds from time to time received, receivable or otherwise distributed from or by the Company in respect of or in exchange for any or all of the Pledged Interests;     

		
	(e)
	all general intangibles consisting of rights of a Shareholder (as defined in the Articles of Association) under the Organizational Documents, including rights to payment, damages, liquidated damages and enforcement in connection therewith;     

		
	(f)
	all general intangibles consisting of contract rights under the Escrow Agreement and the Transfer Deed to obtain the release of the Pledged Interests or any Dividends, including all reversionary rights to the Pledged Interests and rights to damages and enforcement in connection therewith;     

		
	(g)
	to the extent a Lien may be granted thereon under applicable law, all books, records and other written, electronic or other documentation in whatever form maintained now or hereafter by or for the Grantor in connection with, and relating to, the ownership of, or evidencing or containing information relating to, the foregoing; and     

		
	(h)
	all proceeds, supporting obligations and products of any of the foregoing and all collateral security and guarantees given by any Person with respect to any of the foregoing.     

		
	2.2
	Collateral descriptions inclusive     

The inclusion of any item or type of property in any clauses in article 2.1 or in any of the defined terms used therein does not imply the exclusion of such item or type of property from any of the other clauses of article 2.1 or any of the definitions used therein.     
		
	2.3
	No assumption of liability     

The security interest hereunder is granted as security only and does not subject the Secured Party to any obligation or liability of the Grantor with respect to or arising out of any of the Collateral or in any way alters or modifies such obligations or liabilities. The Grantor remains liable under each agreement, interest or obligation included in the Collateral to observe and perform the conditions and obligations to be observed and performed by the Grantor thereunder, all in accordance with and pursuant to the terms and provisions thereof. The Secured Party’s exercise of any of its rights under this deed do not release the Grantor from any of its duties or obligations under any agreement, interest or obligation included in the Collateral.     
		
	2.4
	Consent to transfer     

The Secured Party consents to and authorizes the transfer of the Class A Share and the Preferred Shares to the Escrow Agent pursuant to the terms of the Transfer Deed and the Escrow Agreement so long as the Lien granted pursuant to this deed continues in the Collateral notwithstanding such transfer. The Lien granted pursuant to this deed attaches to the Collateral prior to the transfer of the Class A Share and the Preferred Shares to the Escrow Agent. For purposes of clarity, the Secured Party does not authorize the transfer of the Class A Share or the Preferred Shares to the Escrow Agent free of the Lien granted hereunder.     

A17046371                                           Linklaters LLP

8

		
	2.5
	Dividends     

Notwithstanding the Lien granted pursuant to this deed, until such rights are revoked under article 5.1(d) or an Insolvency Proceeding occurs, the Grantor is authorized to receive and retain any Dividends and to exercise any other right it has in respect of Dividends so long as the exercise of such rights is not otherwise prohibited by the terms of any Transaction Document or Organizational Document.     
		
	2.6
	Voting     

Notwithstanding the Lien granted pursuant to this deed, the Grantor is entitled to exercise or direct the exercise of the voting rights attached to the Pledged Interests so long as the exercise of such rights is not prohibited by the terms of any Transaction Document or Organizational Document.     
		
	2.7
	Organizational documents     

Neither this deed nor the Lien granted pursuant to this deed prohibits the Grantor from exercising any of its rights under the Organizational Documents that constitute Collateral prior to the sale or disposition of such right pursuant to article 5.     
		
	2.8
	Meeting rights     

Notwithstanding the Lien granted pursuant to this deed, the Secured Party does not have the meeting rights as referred to in Section 2:227, subsection 1, of the Dutch Civil Code nor the rights which Dutch law attributes to holders of depository receipts (certificaten van aandelen) with such meeting rights.     
		
	2.9
	Power of attorney     

The Grantor appoints the Secured Party as its true and lawful attorney-in-fact and in such capacity, upon the occurrence and during the continuance of an Event of Default, the Secured Party has, without any further action required by the Grantor, with full power of substitution and in the name of the Grantor or otherwise, the right to:     
		
	(a)
	discharge past due taxes, assessments, charges, fees or Liens on the Collateral (other than any Lien arising under the Escrow Agreement or the Transfer Deed);     

		
	(b)
	commence and prosecute any and all suits, actions or proceedings at law or in equity in or before any court or other tribunal (including any arbitration proceedings) to collect or otherwise realize on all or any of the Collateral, or to enforce any rights of the Grantor in respect of the Collateral (other than any such suits, actions or proceedings against the Secured Party or the Company), including to defend title to the Collateral against any Person and to defend the validity, enforceability, perfection, effectiveness and priority of the security interest of the Secured Party in the Collateral against any Lien (other than any Lien arising under the Escrow Agreement or the Transfer Deed);     

		
	(c)
	settle, compromise, compound, adjust or defend any actions, suits or proceedings relating to any of the Collateral (other than any such suits, actions or proceedings against the Secured Party or the Company);     

		
	(d)
	exercise all other rights, powers, privileges and remedies to which a holder of the Pledged Interests would be entitled under this deed, the Organizational Documents or applicable law; or     

		
	(e)
	use, sell, assign, transfer, pledge, make any agreement with respect to or otherwise deal with the Collateral, and to do all other acts and things necessary or appropriate to carry out the intent and purposes of this deed, as 

A17046371                                           Linklaters LLP

9

fully and completely as though the Secured Party were the absolute owner of the Collateral for all purposes, in all cases in accordance with the terms of, and subject to the limitations set forth in (including with respect to voting rights), this deed.     
Nothing in this article 2.9 requires or obligates the Secured Party to take any action with respect to the Collateral or the monies due or to become due in respect thereof or any property covered thereby, and no action taken or omitted to be taken by the Secured Party with respect to the Collateral in accordance with this deed gives rise to any defense, counterclaim or offset in favor of the Grantor or to any claim or action against the Secured Party. The provisions of this article 2.9 do not relieve the Grantor of its obligations under this deed or impose any obligation on the Secured Party to proceed in any particular manner, or in any way limit the exercise by the Secured Party of any other or further right it may have, whether under this deed, the other Transaction Documents, the Organizational Documents, by law or otherwise. The appointment of the Secured Party as the Grantor’s attorney-in-fact for the purposes set forth in this article 2.9 is a presently effective appointment, is coupled with an interest and is irrevocable until the termination of the agreement laid down in this deed pursuant to article 6.12.     
		
	2.10
	Authorization and ratification of financing statements     

The Grantor authorizes the Secured Party to file all financing statements and other documents to maintain a perfected security interest in the Collateral. Any financing statement filed by the Secured Party may be filed in any filing office in any UCC jurisdiction and may (a) indicate the Collateral by any description which reasonably approximates the description contained in this deed and (b) contain any other information required by the UCC or any filing office. The Grantor ratifies its authorization for the Secured Party to have filed in any UCC jurisdiction any initial financing statements or amendments thereto if filed prior to the date hereof.     
		
	2.11
	Indemnity     

The Grantor shall indemnify the Secured Party and its Affiliates, directors, officers, employees, agents and advisors (each such Person being called an “Indemnitee”) against, and shall hold each Indemnitee harmless from, any and all losses, claims, damages, penalties, liabilities and related expenses, including the fees, charges and disbursements of any counsel for any Indemnitee, incurred by or asserted against any Indemnitee arising out of, in connection with, or as a result of (a) the execution or delivery of this deed or any agreement, instrument or other document contemplated hereby in connection with the Lien granted hereunder, the performance by the Parties of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby or (b) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory and regardless of whether any Indemnitee is a party thereto; provided that the indemnity provided under this article 2.11 is not, as to any Indemnitee, available to the extent that such losses, claims, damages, penalties, liabilities or related expenses are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or wilful misconduct of such Indemnitee.     

A17046371                                           Linklaters LLP

10

		
	3
	Representations     

The Grantor makes the following representations to the Secured Party, which representations survive the execution and delivery of this deed:     
		
	3.1
	Authority     

The execution and delivery of this deed, the performance of its obligations hereunder and the granting of the security interest in the Collateral to the Secured Party pursuant hereto (a) are within the Grantor’s organizational power and authority, (b) have been authorized by all necessary organizational action by the Grantor and (c) do not require the consent or approval of any other Person other than any consent or approval that has been obtained.     
		
	3.2
	Title and liens     

The Grantor has rights in the Collateral or the power to transfer rights in the Collateral to the Secured Party. The Collateral is not encumbered by any Liens (other than any Lien arising under the Escrow Agreement or the Transfer Deed). No financing statement or other public notice with respect to any part of the Collateral is on file or of record in any public office, and the Grantor has not authorized any such filing or recording other than as provided by article 2.10.     
		
	3.3
	Perfection     

All filings, notifications and actions required by the terms of this deed to have been given, made, obtained or accomplished have been or, contemporaneously with the execution and delivery of this deed will be, given, made, obtained and accomplished and, after giving effect to such filings, notifications and actions, the security interest granted in the Collateral pursuant to this deed is perfected to the maximum extent a security interest can be perfected under the UCC of any applicable jurisdiction.     
		
	3.4
	Pledged interests     

Schedule 1 attached to this deed sets forth as of the date hereof (a) the Company’s legal name, jurisdiction of organization and type of entity, (b) the number of shares and type or class thereof for all the Company’s Equity Interests and (c) the number of shares and type or class thereof for the Company’s Equity Interests owned by the Grantor. None of the Pledged Interests are certificated. No Collateral is held by a securities intermediary. There are no warrants, options or other rights entitling the Grantor to purchase or acquire any Equity Interests, except as provided in the Transaction Documents and the Organizational Documents.     
		
	3.5
	Grantor information     

Schedule 2 attached to this deed sets forth, as of the date hereof, the Grantor’s (a) legal name, (b) type of entity, (c) address for its place of business or, if it has more than one place of business, its chief executive office, (d) jurisdiction of organization and (e) organizational identification number issued to it by its jurisdiction of organization, if applicable. During the four months prior to the date hereof (or, if less, since the date of formation of the Grantor), the Grantor has not (i) changed its type of entity or jurisdiction of organization or (ii) been a party to any merger, consolidation or acquisition.     
		
	4
	Covenants     

Until the Termination Date:     
		
	4.1
	Liens     

A17046371                                           Linklaters LLP

11

The Grantor shall not create, incur or suffer to exist any Lien on the Collateral (other than any Lien arising under the Escrow Agreement or the Transfer Deed). The Grantor shall not authorize the filing of any financing statement or other public notice naming it as debtor covering any portion of the Collateral (other than in favor of the Secured Party).     
		
	4.2
	Notices     

The Grantor shall promptly notify the Secured Party in writing (in reasonable detail) of the imposition of any Lien on any of the Collateral (other than any Lien arising under the Escrow Agreement or the Transfer Deed).     
		
	4.3
	Disposition of collateral     

The Grantor shall not sell, transfer or otherwise dispose of any Collateral other than as permitted under article 2.4.     
		
	4.4
	Fundamental changes     

The Grantor shall not change (a) its legal name, (b) its type of entity, (c) its place of business or, if it has more than one place of business, its chief executive office, (d) its jurisdiction of formation or (e) its federal employee identification number or, if applicable, the organizational identification number issued to it by its jurisdiction of organization, in each case unless it has given the Secured Party written notice of such change at least ten (10) days prior to such change and taken any reasonable action requested by the Secured Party to continue the perfection of any of its Liens in the Collateral. Notwithstanding the foregoing, the Grantor shall not relocate its place of business or, if it has more than one place of business, its chief executive office outside of the United States of America.     
		
	4.5
	Pledged interests     

		
	(a)
	The Grantor shall deliver to the Secured Party all certificates or instruments, if any exist and are in the possession or control of the Grantor, evidencing the Pledged Interests, duly indorsed in blank pursuant to an undated stock power or such other instruments of transfer as are reasonably acceptable to the Secured Party.     

		
	(b)
	The Grantor, to the extent it has the power to do so, shall not permit any uncertificated security constituting Pledged Interests to become certificated.     

		
	(c)
	The Grantor shall permit the Secured Party from time to time to cause the Company to mark its books and records with the numbers and face amounts of all Pledged Interests and all rollovers and replacements therefor to reflect the Lien of the Secured Party.     

		
	4.6
	Further assurances     

The Grantor shall duly execute, acknowledge and deliver all such agreements, instruments and other documents and take all such reasonable actions as the Secured Party may from time to time reasonably request to better assure, preserve, protect and perfect the security interest of the Secured Party in the Collateral, and the rights and remedies of the Secured Party hereunder, or otherwise to further effectuate the intent and purposes of this deed and to carry out the terms hereof.     
		
	5
	Remedies     

		
	5.1
	Remedies generally     

Upon the occurrence and during the continuation of an Event of Default, the Secured Party may:     

A17046371                                           Linklaters LLP

12

		
	(a)
	exercise those rights and remedies available to a secured party under the UCC (whether or not the UCC applies to the affected Collateral) or under any other applicable law (including the laws of the Netherlands) when a debtor is in default under a security agreement;     

		
	(b)
	to the extent permitted by applicable law, sell or otherwise dispose of any of the Collateral at public or private sales and take possession of the proceeds of any such sale or disposition;     

		
	(c)
	to the extent permitted by applicable law, transfer and register in its name or in the name of its nominee the whole or any part of the Pledged Interests, exchange certificates or instruments representing or evidencing Pledged Interests for certificates or instruments of smaller or larger denominations, exercise all rights (other than voting rights) as a holder with respect thereto, including exchange, subscription or any other rights, privileges or options pertaining to any Pledged Interests, and otherwise act with respect to the Pledged Interests as though the Secured Party was the absolute owner thereof;     

		
	(d)
	to the extent permitted by applicable law, revoke by written notice to the Escrow Agent (with a copy to the Company and the Grantor) the authorization granted under article 2.5 and, after such authorization is revoked or if an Insolvency Proceeding has occurred, collect and receive all Dividends and other distributions made on any Pledged Interests and exercise any other right with respect to Dividends, in each case to the exclusion of the Grantor;     

		
	(e)
	exercise the Grantor’s rights and remedies (i) against the Escrow Agent or (ii) with respect to the Class A Share or the Preferred Shares under the Escrow Agreement or the Transfer Deed in each case as necessary or desireable to obtain the release of the Pledged Interests or any Dividends, including all reversionary rights to the Pledged Interests; and     

		
	(f)
	exercise those other rights and remedies of the Secured Party provided in this deed, any other Transaction Document or any Organizational Documents.     

		
	5.2
	Dispositions     

		
	(a)
	Subject to article 5.2(g), any Collateral to be sold or otherwise disposed of pursuant to article 5.1 may be sold or disposed of in one or more parcels at public or private sale or sales (which sales may be adjourned or continued from time to time with or without notice (other than as required by law) and may take place at the Grantor’s premises or elsewhere) upon such terms and conditions as the Secured Party may deem commercially reasonable and at such prices as it may deem best, for cash or on credit or for future delivery without assumption of any credit risk. Any sale or disposition of Collateral may be made without the Secured Party giving warranties of any kind with respect to such sale or disposition and the Secured Party may specifically disclaim any warranties of title or the like.     

		
	(b)
	The Secured Party may comply with any applicable state, federal or other applicable law requirements in connection with a sale or disposition of the Collateral and compliance will not be considered to adversely affect the commercial reasonableness of any such sale or disposition. If any notice of a proposed sale or disposition of the Collateral is required by law, such notice is 

A17046371                                           Linklaters LLP

13

deemed commercially reasonable and proper if given at least ten (10) days before such sale or disposition. The Secured Party is not required to notify any Person (other than as required by law) who has a limited right in relation to, or has a Lien on, any Collateral of any proposed or completed sale or disposition of Collateral and only the Secured Party has the right referred to in Section 3:251, subsection 1, of the Dutch Civil Code to make an application to the court for a different method of sale or disposition of Collateral.     
		
	(c)
	The Secured Party has the right upon any public sale of Collateral and, to the extent permitted by applicable law, upon any such private sale of Collateral, to purchase the whole or any part of the Collateral so sold or disposed of free of any right of equity redemption, which equity redemption the Grantor hereby waives. Upon any sale or disposition of Collateral, the Secured Party has the right to deliver and transfer to the purchaser or transferee thereof the Collateral so sold or disposed of.      

		
	(d)
	Until the Secured Party is able to effect a sale or disposition of the Collateral, the Secured Party has the right to hold or use the Collateral, or any part thereof, for any purpose deemed appropriate by the Secured Party in accordance with the terms hereof and of the Transaction Documents and the Organizational Documents and applicable law.     

		
	(e)
	The Grantor recognizes that the Secured Party may be unable to effect a public sale of any or all the Collateral and may be compelled to resort to one or more private sales thereof. The Grantor acknowledges that any private sale may result in prices and other terms less favorable to the seller than if such sale were a public sale and, notwithstanding such circumstances, agrees that any such private sale is not deemed to have been made in a commercially unreasonable manner solely by virtue of such sale being private. The Secured Party is under no obligation to delay a sale of any of the Collateral for the period of time necessary to permit the Grantor or the Company to register Pledged Interests for public sale under the Securities Act of 1933, as amended, or under applicable federal, state or other applicable securities laws.     

		
	(f)
	The Secured Party shall apply the net proceeds of any action taken by it pursuant to this article 5.2, after deducting all reasonable costs and expenses of every kind incurred in connection therewith or incidental to the care or safekeeping of any of the Collateral or in any way relating to the Collateral or the rights of the Secured Party hereunder, including attorneys’ fees and disbursements, to the payment in whole or in part of the Secured Obligations, in such order as the Secured Party may elect, and only after such application and after the payment by the Secured Party of any other amount required by any provision of law need the Secured Party account for the surplus, if any, to the Grantor or such other Person as a court of competent jurisdiction directs.     

		
	(g)
	Notwithstanding anything in article 5.1 or this article 5.2 to the contrary, (i) the Secured Party may not exercise its rights and remedies under this deed, including its right to sell or otherwise dispose of the Collateral, unless the Grantor has breached any of its obligations with respect to the Purchase Option or the Right of First Offer, and (ii) the Secured Party will not directly or 

A17046371                                           Linklaters LLP

14

indirectly purchase or otherwise acquire the Collateral pursuant to the Purchase Option, this article 5.2 or through liquidated damages pursuant to article 6.2 or section 12.18 of the Shareholders Agreement for an amount less than the sum of the Class A Loan Amount plus the Preferred Shares Option Price (as such terms are defined in the Articles of Association), in each case, it being understood that such price shall be subject to satisfaction by dollar-for-dollar or euro-for-euro offset, or credit bid, as the case may be, up to the amount then outstanding under the Convertible Notes and the Class A Note, after giving effect to acceleration. Promptly following the closing of its purchase, sale or other disposition of the entirety of the Collateral pursuant to article 5.1 (it being understood that the Secured Party may have acquired the Class A Share prior to completion of its acquisition of the balance of the Collateral), the Secured Party will deliver the Class A Note and all of the issued and outstanding Convertible Notes to the Grantor (provided, that such obligation to deliver the Class A Note and the Convertible Notes shall not constitute a condition subsequent to the effectiveness of such purchase, sale 
or other disposition), and the Class A Note and such Convertible Notes will be cancelled and extinguished by the Secured Party. The Secured Party’s compliance with the terms of this article 5.2(g) are deemed commercially reasonable.     
		
	5.3
	Grantor’s obligations upon default     

Upon the request of the Secured Party after the occurrence and during the continuation of an Event of Default, the Grantor shall:     
		
	(a)
	assemble and make available to the Secured Party all books and records relating to the Collateral as specified by the Secured Party to the extent not otherwise in the possession or control of the Secured Party; and     

		
	(b)
	hold all Dividends and other distributions made on any Pledged Interests it receives in trust for the benefit of the Secured Party, segregated from the other property or funds of the Grantor, and promptly deliver such Dividends and other distributions to the Secured Party as Collateral in the same form as so received (with any necessary endorsement).     

		
	5.4
	Remedies cumulative and waiver     

The rights and remedies of the Parties under this deed are cumulative and are not exclusive of any rights or remedies that they would otherwise have. Notwithstanding anything in this deed to the contrary (except as provided in article 5.2(g)), the Secured Party is not required to (a) make any demand upon, or pursue or exhaust any of its rights or remedies against, the Grantor, any other obligor, guarantor, pledgor or any other Person with respect to the payment of the Secured Obligations or to pursue or exhaust any of its rights or remedies with respect to any Collateral therefor or any direct or indirect guarantee thereof or (b) marshal the Collateral or any guarantee of the Secured Obligations or to resort to the Collateral or any such guarantee in any particular order. To the extent permitted by applicable law, the Grantor waives all claims, damages and demands it may acquire against the Secured Party arising out of the exercise by them of any rights hereunder, except to the extent that such claims, damages or demands are determined by a court of competent jurisdiction to have resulted from the gross negligence or willful misconduct of the Secured Party. To the

A17046371                                           Linklaters LLP

15

maximum extent permitted by applicable law that following the occurrence and during the continuance of an Event of Default, the Grantor shall not plead, claim or take the benefit of any appraisal, valuation, stay, extension, moratorium or redemption law now or hereafter in force to prevent or delay the enforcement of this deed, or the absolute sale of the whole or any part of the Collateral or the possession thereof by any purchaser at any sale hereunder, and the Grantor waives the benefit of all such laws to the extent it lawfully may do so. The Grantor shall not interfere with any right, power and remedy of the Secured Party provided in this deed or now or hereafter existing at law or in equity or by statute or otherwise, or the exercise or beginning of the exercise by the Secured Party of any one or more of such rights, powers or remedies.     
		
	6
	Miscellaneous     

		
	6.1
	Waiver of automatic stay     

In the event that an Insolvency Proceeding occurs, the Secured Party is entitled to relief from any automatic stay imposed by section 362 of the United States Bankruptcy Code, or otherwise, to allow the Secured Party to exercise its rights and remedies under this deed, and as otherwise provided by law, including taking possession of the Collateral, foreclosing its lien, or otherwise exercising its remedies with respect to the Collateral. In such event, the Grantor unconditionally and irrevocably waives the benefit of such automatic stay and shall not, in any manner, oppose or otherwise delay any motion filed by the Secured Party for relief from the automatic stay. The Secured Party’s enforcement of the right granted herein for relief from the automatic stay is subject to the approval of the bankruptcy court in which the case is then pending.     
		
	6.2
	Liquidated damages     

The Grantor acknowledges that because the Preferred Shares Option Price is subject to a fair market value determination as provided by the Valuation Advisor, and that the Secured Party’s rights pursuant to the Right of First Offer are subject to valuation as provided by a third party purchase offer, and that, in each case, the Secured Party is permitted to offset the full amounts then outstanding under the Convertible Notes against the Preferred Share Option Price or, as applicable, the price determined in accordance with the Right of First Offer, it is difficult and impractical to ascertain the actual and anticipated damages that the Secured Party would suffer by reason of the failure of the Grantor to perform any of its obligations with respect to the Purchase Option or the Secured Party’s rights pursuant to the Right of First Offer. Consequently, if the Grantor breaches any of its material obligations with respect to the Purchase Option or the Secured Party’s rights pursuant to the Right of First Offer, the Grantor shall pay to the Secured Party, as liquidated damages and not as a penalty, an amount equal to the full obligations outstanding under the Convertible Notes at the time of such breach after giving effect to acceleration, and the Grantor and the Secured Party acknowledge that such damage calculation is a fair and reasonable estimate of the actual and anticipated damages that the Secured Party would suffer as a result of such breach, provided, however, that such liquidated damages shall not be duplicative of the obligations outstanding under the Convertible Notes or the damages as provided in section 12.18 of the Shareholders Agreement. If the liquidated damages described above are held to be invalid, illegal or unenforceable in any jurisdiction, then the Secured Party shall have such other rights, remedies and 

A17046371                                           Linklaters LLP

16

damages as are provided hereby, by applicable law and any other agreements with the Grantor, all of which are reserved. The Grantor acknowledges that any damages provided hereby are Secured Obligations that are secured under this deed and that the Secured Party may, pursuant to applicable law, purchase the Collateral and apply such damages to the purchase price thereof. To the extent that the Secured Party applies any damages provided hereby toward the purchase price of Collateral under this deed, the obligations under the Convertible Notes will be deemed repaid in full.     
		
	6.3
	Governing law     

The agreement laid down in this deed is governed by, and construed in accordance with, the laws of the State of New York, United States of America. To the extent the Lien created by this deed needs to be treated as a Lien governed by the laws of any jurisdiction other than the State of New York, United States of America, under any applicable conflict of law principle or otherwise, the Parties explicitly confirm their intention to create such a Lien under the laws of such other jurisdiction. The use in this deed of any terms relevant for the creation of a Liens under the laws of the State of New York will not be construed as excluding any the creation of a Lien under other applicable legal systems, and any such relevant terms will be construed as reference to the appropriate concepts of such other applicable legal systems.     
		
	6.4
	Taxes and expenses     

The Grantor shall pay any taxes (including income taxes) payable or ruled payable by federal or state authority in respect of this deed, together with interest and penalties, if any. The Grantor shall indemnify, reimburse, and hold harmless the Secured Party from and against all reasonable costs and expenses incurred in connection with the enforcement of this deed, including reasonable attorneys’ fees and expenses. Any and all costs and expenses incurred by the Grantor in the performance of actions required pursuant to the terms of this deed shall be borne solely by the Grantor.     
		
	6.5
	Severability     

Any provision of this deed held to be invalid, illegal or unenforceable in any jurisdiction is, as to such jurisdiction, ineffective to the extent of such invalidity, illegality or unenforceability without effecting the validity, legality and enforceability of the remaining provisions of this deed; and the invalidity of a particular provision in a particular jurisdiction does not invalidate such provision in any other jurisdiction.     
		
	6.6
	Integration     

This deed, the other Transaction Documents and the Organizational Documents constitute the entire understanding between the Parties relating to the subject matter hereof and supersedes any and all previous agreements and understandings, oral or written, relating to the subject matter hereof.     
		
	6.7
	Notices     

All notices and other communications provided for in this deed must be in writing and delivered in the manner provided in the Purchase Agreement.     
		
	6.8
	Amendments     

Neither this deed nor any provision hereof may be amended, modified or waived except pursuant to an agreement or agreements in writing entered into by the Parties (and, where relevant, the Company) and, if required under the laws of the Netherlands, such agreements will be effectuated by means of a Dutch notarial deed to be executed before a civil law notary in the Netherlands.     

A17046371                                           Linklaters LLP

17

		
	6.9
	No implied waivers     

No failure to exercise and no delay in exercising any right or remedy under this deed operates as a waiver thereof. No single or partial exercise of any right or remedy under this deed, or any abandonment or discontinuance thereof, precludes any other or further exercise thereof or the exercise of any other right or remedy. No waiver or consent under this deed is applicable to any events, acts or circumstances except those specifically covered thereby.     
		
	6.10
	Successors and assigns     

This deed is binding upon, and inures to the benefit of, the Parties and their respective successors and permitted assigns. The Grantor may not assign or transfer any of its interests or rights, or delegate its duties or obligations, under this deed, in whole or in part, without the prior written consent of the Secured Party. The Secured Party may assign or transfer any of its interests, rights or remedies, and delegate its duties or obligations, under this deed in connection with an assignment or transfer of its interests under the Transaction Documents or the Organizational Documents. Nothing in this deed, expressed or implied, may be construed to confer upon any Person (other than the Parties, their respective successors and permitted assigns) any legal or equitable right, remedy or claim under or by reason of this deed.     
		
	6.11
	Submission to jurisdiction and waiver of jury trial     

		
	(a)
	The Parties (and, where relevant, the Company) agree that any action or proceeding with respect to this deed or any judgment entered by any court in respect thereof may be brought in the United States District Court for the Southern District of New York or the courts of the State of New York and the competent courts of Amsterdam, the Netherlands, and each Party (and, where relevant, the Company) submits to the jurisdiction of such courts for the purpose of any such action, proceeding or judgment.     

		
	(b)
	Each Party (and, where relevant, the Company) irrevocably consents to service of process in the manner provided for notice in article 6.7 and, to the extent required, they elect domicile at the address provided in article 6.7 for such purpose. Nothing in this deed affects the right of any Party (and, where relevant, the Company) to service process in any other manner permitted by applicable law.     

		
	(c)
	Each Party (and, where relevant, the Company) irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this deed in any court referred to in article 6.11(a). Each Party (and, where relevant, the Company) irrevocably waives, to the fullest extent permitted by applicable law, the defence of an inconvenient forum to the maintenance of such action or proceeding in any such court.     

		
	(d)
	EACH PARTY (AND, WHERE RELEVANT, THE COMPANY) IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATED TO THIS DEED OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER REASON).     

A17046371                                           Linklaters LLP

18

		
	6.12
	Termination and reinstatement     

		
	(a)
	The agreement laid down in this deed continues in effect (notwithstanding the fact that from time to time there may be no Secured Obligations outstanding) until the Termination Date. Upon the Termination Date (regardless of whether there are any Secured Obligations remaining outstanding as of the Termination Date), the agreement laid down in this deed, the Liens created under this deed and the Secured Party’s rights and the Grantor’s obligations under this deed with regard to any such Liens shall terminate and upon such termination the Secured Party hereby authorizes the Grantor to file any UCC termination statements necessary to effect such termination, and the Secured Party will, at the Grantor’s expense, promptly execute and deliver to the Grantor any additional documents or instruments as the Grantor shall reasonably request to evidence such termination. Notwithstanding anything in this deed to the contrary, the Secured Party may at any time, at the cost of the Grantor, unilaterally terminate the Liens created under this deed by written notice to the Grantor.     

		
	(b)
	If at any time payment of the Secured Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Secured Obligations, whether as a “voidable preference”, “fraudulent conveyance” or otherwise, all as though such payment or performance had not been made, then the agreement laid down in this deed is reinstated (unless the Termination Date has occurred even if the Secured Obligations had not been repaid) and the Secured Obligations are deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.     

		
	6.13
	Waiver of rescission and nullification     

The Grantor and the Company irrevocably waive any right under any applicable law to rescind or nullify the agreement laid down in this deed in whole or in part and any right to suspend any obligation under this deed.     
		
	6.14
	Acknowledgement of Notary     

The Notary is a civil law notary holding office with Linklaters LLP, the Secured Party’s Dutch legal adviser. The Grantor, the Secured Party and the Company acknowledge that they have been informed of the existence of the Ordinance Containing Rules of Professional Conduct and Ethics (Verordening beroeps- en gedragsregels) of the Royal Professional Organisation of Civil Law Notaries (Koninklijke Notariële Beroepsorganisatie) and explicitly agree and acknowledge (a) that Linklaters LLP may advise and act on behalf of the Secured Party with respect to this deed and any agreements or any disputes related to or resulting from this deed and (b) that the Notary holding office with Linklaters LLP executes this deed.     
		
	6.15
	Expenses     

All costs and expenses incurred in connection with the negotiation and drafting of this deed shall be borne by the Party incurring such costs and expenses.     
		
	6.16
	Acknowledgement by Company     

The Company acknowledges the Lien created by this deed and shall enter such Lien in its register in accordance with and as referred to in Section 2:194 of the Dutch Civil Code and provide the Secured Party with an extract from the register, in respect of
the 

A17046371                                           Linklaters LLP

19

Pledged Interests, promptly after the execution of this deed and in respect of Pledged Interests to be acquired after the execution of this deed, promptly after becoming aware of the Grantor’s acquisition of any such Pledged Interests.     
The Company shall comply with the instructions originated by the Secured Party without further consent by the Grantor. The Company declares that it has taken notice of the terms and conditions of this deed and shall fully cooperate with the performance thereof, and that it is not aware of any facts or circumstances that in any way would cause any of the Grantor’s representations under this deed to be incorrect in any material respect.     
Close     
The person appearing is known to me, civil law notary.     
This deed was executed in Amsterdam, the Netherlands, on the date first above written. Before reading out, a concise summary and an explanation of the contents of this deed were given to the person appearing. The person appearing then declared that he had taken note of and agreed to the contents of this deed and did not want the complete deed to be read to him. Thereupon, after limited reading, this deed was signed by the person appearing and by me, civil law notary.     
(Signed by: P.J. Suurd; B.J. Kuck)

	
		
	 
	TRUE COPY:

A17046371                                           Linklaters LLP

20

SCHEDULE 1 
Pledged Interests

	
		
	(c)    the Company’s legal name, jurisdiction of organization and type of entity
	Total Amyris BioSolutions B.V., a private company with limited liability incorporated under the laws of the Netherlands (besloten vennootschap met beperkte aansprakelijkheid)

	(d)    the number of shares and type or class thereof for all the Company’s Equity Interests
	1 voting share A
1 voting share B
2 preference shares

	(e)    the number of shares and type or class thereof for the Company’s Equity Interests owned by the Grantor
	1 voting share A
2 preference shares

A17046371                                           Linklaters LLP

21

SCHEDULE 2 
Grantor Information

	
		
	(a)    legal name
	Amyris, Inc.

	(b)    type of entity
	Corporation

	(c)    address for its place of business or, if it has more than one place of business, its chief executive office
	5885 Hollis Street, Suite 100 
Emeryville, CA 94608, United States of America

	(d)    jurisdiction of organization
	Delaware

	(e)    organizational identification number issued to it by its jurisdiction of organization, if applicable
	4768633
Secretary of State of the State of Delaware, United States of America

A17046371                                           Linklaters LLP

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]